Page last updated: 2024-11-11

nifurtimox

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nifurtimox: A nitrofuran thiazine that has been used against TRYPANOSOMIASIS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6842999
CHEMBL ID290960
CHEBI ID7566
CHEBI ID91472
SCHEMBL ID1650162
MeSH IDM0014852

Synonyms (90)

Synonym
BRD-A84020532-001-03-5
PRESTWICK2_001024
NCGC00016774-01
cas-23256-30-6
BPBIO1_001329
BSPBIO_001207
PRESTWICK3_001024
lampit
3-methyl-n-[(5-nitro-2-furanyl)methylene]-4-thiomorpholinamine 1,1-dioxide
bayer 2502
n-(3-methyl-1,1-dioxo-1,4-thiazinan-4-yl)-1-(5-nitro-2-furyl)methanimine
C08002
nifurtimox
23256-30-6
D00833
lampit (tn)
nifurtimox (usan/inn)
4-thiomorpholinamine, 3-methyl-n-((5-nitro-2-furanyl)methylene)-, 1,1-dioxide
nifurtimox [inn:ban]
nifurtimoxum [inn-latin]
ccris 2201
einecs 245-531-0
thiomorpholine, 3-methyl-4-((5-nitrofurfurylidene)amino)-, 1,1-dioxide
3-methyl-4-(5'-nitrofurylidene-amino)-tetrahydro-4h-1,4-thiazine-1,1-dioxide
tetrahydro-3-methyl-4-((5-nitrofurfurylidene)amino)-2h-1,4-thiazine 1,1-dioxide
1-((5-nitrofurfurylidene)amino)-2-methyltetrahydro-1,4-thiazine-4,4-dioxide
4-((5-nitrofurfurylidene)amino)-3-methylthiomorpholine 1,1-dioxide
4-((5-nitrofurfurylidene)amino)-3-methylthiomorpholine-1,1-dioxide
dndi1613515
nifurtimoxum
bay-2502
bay-a2502
CHEMBL290960
bayer-2502
chebi:7566 ,
(+/-)-nifurtimox
dtxsid3045439 ,
dtxcid1025439
tox21_110604
BRD-A84020532-001-04-3
m84i3k7c2o ,
unii-m84i3k7c2o
S6459
tetrahydro-3-methyl-4-((5-nitrofurfurylidene)amino)-4h-1,4-thiazine 1,1-dioxide
nifurtimox [inn]
4-[(5-nitrofurfurylidene)amino]-3-methylthiomorpholine 1,1-dioxide
nifurtimox [orange book]
nifurtimox [who-dd]
nifurtimox [mart.]
nifurtimox [usan]
(rs)-3-methyl-n-((1e)-(5-nitro-2-furyl)methylene)thiomorpholin-4-amine 1,1-dioxide
nifurtimoxum [who-ip latin]
nifurtimox [who-ip]
nifurtimox [mi]
SCHEMBL1650162
ksc-427-39-1
KUC114565N
4-thiomorpholinamine, 3-methyl-n-[(5-nitro-2-furanyl)methylene]-, 1,1-dioxide
AKOS030527688
SR-01000838852-2
sr-01000838852
CHEBI:91472
nifurtimox, >=98% (hplc)
J-015055
DB11820
CS-W020813
HY-W040073
bay2502
3-methyl-4-(((5-nitrofuran-2-yl)methylene)amino)thiomorpholine 1,1-dioxide
bdbm50259708
unii-1g5dd3p35c
(+)-nifurtimox
unii-x4kcv4zi9m
nifurtimox, (-)-
4-thiomorpholinamine, 3-methyl-n-((5-nitro-2-furanyl)methylene)-, 1,1-dioxide, (-)-
(-)-nifurtimox
1g5dd3p35c ,
39072-15-6
4-thiomorpholinamine, 3-methyl-n-((5-nitro-2-furanyl)methylene)-, 1,1-dioxide, (+)-
nifurtimox, (+)-
EX-A4624
A912676
MS-24101
SR-01000838852-3
(E)-3-METHYL-4-(((5-NITROFURAN-2-YL)METHYLENE)AMINO)THIOMORPHOLINE 1,1-DIOXIDE
EN300-21039719
3-methyl-4-[(e)-[(5-nitrofuran-2-yl)methylidene]amino]-1lambda6-thiomorpholine-1,1-dione
nifurtimoxum (inn-latin)
nifurtimox (mart.)
p01cc01

Research Excerpts

Overview

Nifurtimox (NFX) is a nitrofuran derivative used to treat Chagas disease, a neglected disease caused by the protozoan Trypanosoma cruzi. The drug is a high clearance compound (15.23 +/- 5.53 mL min-1)

ExcerptReferenceRelevance
"Nifurtimox (NFX) is a nitrofuran derivative used to treat Chagas disease, a neglected disease caused by the protozoan Trypanosoma cruzi. "( Solid-state properties of Nifurtimox. Preparation, analytical characterization, and stability of an amorphous phase.
Calvo, NL; Kaufman, TS; Lionello, DF; Mayoral, EP; Moroni, AB; Vega, DR, 2023
)
2.65
"Nifurtimox is a nitroheterocyclic drug employed for treatment of trypanosomiases (Chagas disease and West African sleeping sickness); its use for certain cancers has also been assessed. "( Selected Aspects of the Analytical and Pharmaceutical Profiles of Nifurtimox.
Calvo, NL; Kaufman, TS; Moroni, AB, 2023
)
2.59
"Nifurtimox is an effective treatment for patients with Chagas disease, but knowledge of its biotransformation and excretion is limited."(
Bairlein, M; Fricke, R; Gerisch, M; Lang, D; Schmuck, G; Schulz, SI; Stass, H, 2023
)
2.35
"Nifurtimox is a recommended treatment for Chagas disease, but data from treated children are limited. "( Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO).
Altcheh, J; Castro, L; Dib, JC; Grossmann, U; Huang, E; Moscatelli, G; Pinto Rocha, JJ; Ramírez, TE, 2021
)
2.27
"Nifurtimox is a 5-nitrofuran derived antiprotozoal drug used to treat diseases caused by trypanosomes including Chagas' disease and sleeping sickness (African trypanosomiasis). "( Determination of nifurtimox in dog plasma by stable-isotope dilution LC-MS/MS.
Gnoth, MJ; Hopfe, PM; Thuss, U, 2015
)
2.2
"Nifurtimox (Nfx) is a drug used in the treatment of Chagas' disease, an endemic parasitic disease from Latin American countries. "( Reactions of nifurtimox with critical sulfhydryl-containing biomolecules: their potential toxicological relevance.
Castro, JA; Díaz, EG; Montalto de Mecca, M,
)
1.94
"Nifurtimox (Nfx) is a nitroheterocyclic drug used in the treatment of Chagas' disease. "( Nifurtimox nitroreductase activity in different cellular fractions from male rat pancreas. Biochemical and ultrastructural alterations.
Bartel, LC; Castro, JA; de Castro, CR; de Mecca, MM; Díaz, EG; Fanelli, SL, 2007
)
3.23
"Nifurtimox is a high clearance compound (15.23 +/- 5.53 mL min-1)."( Disposition of nifurtimox and metabolite activity against Trypanosoma cruzi using rat isolated perfused liver.
González-Martin, G; Guevara, A; Paulos, C; Ponce, G, 1994
)
1.36
"Nifurtimox (Nfx) is a chemotherapeutic agent used in the treatment of acute Chagas' disease. "( [Ultrastructural alterations in colonic mucosa of nifurtimox treated rats].
Castro, JA; Díaz, EG; Montalto de Mecca, M; Rodríguez de Castro, C, 2001
)
2.01

Effects

Nifurtimox (LAMPIT) has been used for decades for the treatment of Chagas disease, a chronic and potentially life-threatening disease caused by the parasite Trypanosoma cruzi.

ExcerptReferenceRelevance
"Nifurtimox (LAMPIT) has been used for decades for the treatment of Chagas disease, a chronic and potentially life-threatening disease caused by the parasite Trypanosoma cruzi. "( Population Pharmacokinetics of Nifurtimox in Adult and Pediatric Patients With Chagas Disease.
Garmann, D; Hanze, E; Ince, I; Prins, K; Sadre-Marandi, F; Stass, H; Sutter, G; Willmann, S, 2022
)
2.45
"Nifurtimox has been used to treat Chagas disease for 40 years, but tolerance and safety data in adults are scarce. "( Tolerance and safety of nifurtimox in patients with chronic chagas disease.
Alirol, E; Chappuis, F; Combescure, C; Getaz, L; Jackson, Y; Wolff, H, 2010
)
2.11
"Nifurtimox has been successfully used to cure melarsoprol-refractory sleeping sickness caused by Trypanosoma brucei gambiense infection."( Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness.
Bisser, S; Būscher, P; Lejon, V; Miaka Mia Bilenge, C; N'Siesi, FX; Preux, PM; Van Nieuwenhove, S, 2007
)
1.33

Treatment

Treatment with nifurtimox (NF) for Chagas disease is discouraged during breast-feeding because no information on NF transfer into breast milk is available.

ExcerptReferenceRelevance
"Nifurtimox treatment inhibited ERK phosphorylation and induced apoptosis in tumor cells."( Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine.
Du, M; Scorsone, KA; Woodfield, SE; Zage, PE; Zhang, L, 2016
)
2.6
"Nifurtimox-treated chagasic animals injected with 2,500 trypomastigotes developed higher parasitemia and increased mortality compared with nontreated chagasic mice."( Differences in resistance to reinfection with low and high inocula of Trypanosoma cruzi in chagasic mice treated with nifurtimox and relation to immune response.
Cabeza Meckert, P; Chambó, JG; Laguens, RP, 1988
)
1.21
"Nifurtimox-treated organisms showed greater amounts of unsaturated fatty acids as compared with control cells."( Lipid alterations induced by nifurtimox in Trypanosoma cruzi.
Barreto-Bergter, E; Hogge, L; Steele da Cruz, F, 1986
)
1.28
"Treatment with nifurtimox (NF) for Chagas disease is discouraged during breast-feeding because no information on NF transfer into breast milk is available. "( Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease.
Altcheh, J; Ballering, G; Bisio, M; García-Bournissen, F; Gonzalez, N; Marson, ME; Mastrantonio, G; Moroni, S; Moscatelli, G, 2019
)
1.18

Toxicity

ExcerptReferenceRelevance
" Studies on Nfx and Bz biotransformation, activation to reactive metabolites, and potential mechanisms for their toxic effects were analyzed."( Toxic effects of nifurtimox and benznidazole, two drugs used against American trypanosomiasis (Chagas' disease).
Castro, JA; Diaz de Toranzo, EG, 1988
)
0.61
" The most frequent adverse effects observed in the use of Nfx are: anorexia, loss of weight, psychic alterations, excitability, sleepiness, digestive manifestations such as nausea or vomiting, and occasionally intestinal colic and diarrhoea."( Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis).
Bartel, LC; Castro, JA; de Mecca, MM, 2006
)
0.33
"4%) patients presented with a suspected unexpected serious adverse reaction: drug reaction with eosinophilia and systemic symptoms (n = 3), Quincke edema (n = 1), acute myocarditis (n = 1), and anaphylaxis (n = 1)."( Tolerance and safety of nifurtimox in patients with chronic chagas disease.
Alirol, E; Chappuis, F; Combescure, C; Getaz, L; Jackson, Y; Wolff, H, 2010
)
0.67
" Safety was further assessed based on treatment emergent adverse events (AEs) occurring during hospitalisation."( In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness.
Blesson, S; Blum, J; Ghabri, S; Ilunga, M; Kande, V; Kisala, M; Kuemmerle, A; Lumpungu, I; Mordt, OV; Mubwa, N; Mutanda, S; Mutombo, W; Nganzobo, P; Schmid, C; Tete, D, 2012
)
0.64
"3%) presented adverse drug reactions (ADRs), and 16 (21."( Safety Profile of Nifurtimox and Treatment Interruption for Chronic Chagas Disease in Colombian Adults.
Álvarez, CA; Cucunubá, ZM; Nicholls, RS; Olivera, MJ, 2015
)
0.75
" The frequency and severity of adverse events (AEs) was recorded."( Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States.
Abuhamidah, A; Forsyth, CJ; Hernandez, S; Meymandi, SK; Olmedo, W; Sanchez, DR; Soverow, J; Traina, MI, 2016
)
0.77
" Study drug-related treatment-emergent adverse events (TEAEs), which were observed in 62 patients (28."( Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO).
Altcheh, J; Castro, L; Dib, JC; Grossmann, U; Huang, E; Moscatelli, G; Pinto Rocha, JJ; Ramírez, TE, 2021
)
0.83
" This report summarizes CDC Drug Service reports for selected characteristics of and adverse events reported by 336 patients for whom nifurtimox was requested under the CDC IND program during January 1, 2001-January 25, 2021."( Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2001-2021.
Abbott, A; Chancey, RJ; Montgomery, SP, 2022
)
1.17
" Overall, 155 (75%) of 208 patients had 600 treatment-emergent adverse events."( Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial.
Akwaso Massa, F; Asuka Akongo Nguba, A; Betu Kumeso, VK; Camara, M; Catusse, J; Delhomme, S; Embana Mankiara, H; Fifi Nzeza Bambuwu, A; Ilunga Wa Kyhi, M; Kalonji, WM; Kaninda Badibabi, L; Kasongo Bonama, A; Kavunga Lukula, P; Kobo Muanza, V; Layba Camara, M; Mahenzi Mbembo, H; Makaya Mayawula, J; Mariero Philemon, P; Mokilifi Nganyonyi, R; Mulenge Nasandhel, E; Mutanda Kalonji, S; Mwamba Miaka, E; Ngolo Tete, D; Nusbaumer, M; Prêtre, A; Rembry, S; Scherrer, B; Schneitter, S; Strub-Wourgaft, N; Tarral, A; Valverde Mordt, O, 2023
)
0.91
" No adverse events potentially related to treatment or caused by protocol-required procedures were documented for either treatment regimen."( Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE).
Altcheh, J; Ding, O; Grossmann, U; Huang, E; Moscatelli, G; Pinto Rocha, JJ; Ramirez, T; Sierra, V, 2023
)
1.22

Pharmacokinetics

The pharmacokinetic (PK) information on nifurtimox in humans derived from controlled clinical studies is very limited. Data from three clinical studies were pooled and analyzed using a time-to-event pharmacodynamic modeling approach.

ExcerptReferenceRelevance
" The patients with chronic renal failure had a higher Cmax than the control subjects due to a change in systemic availability."( The pharmacokinetics of nifurtimox in chronic renal failure.
González-Martin, G; Paredes, J; Paulos, C; Thambo, S; Vásquez, I, 1992
)
0.59
" The pharmacokinetic analysis was carried out according to a one-compartment model and the most important parameters established were elimination half-life, distribution volume, and clearance."( Pharmacokinetics of a nitrofuran compound, nifurtimox, in healthy volunteers.
Arancibia, A; Gonzalez-Martin, G; Paredes, J; Paulos, C; Thambo, S; Vasquez, I, 1989
)
0.54
" The results indicate that the enantiomers are equivalent in their in vitro activity against a panel of Trypanosoma cruzi strains; in vivo efficacy in a murine model of Chagas disease; in vitro toxicity and absorption, distribution, metabolism, and excretion characteristics; and in vivo pharmacokinetic properties."( Enantiomers of nifurtimox do not exhibit stereoselective anti-Trypanosoma cruzi activity, toxicity, or pharmacokinetic properties.
Braillard, S; Charman, SA; Chatelain, E; Cordeiro-da-Silva, A; Freitas-Junior, L; Gaspar, L; Goo, J; Moraes, CB; Perez, C; Shackleford, DM; Thompson, RC; White, KL, 2015
)
0.77
" This work describes the optimization of the pharmacokinetic properties of a previously published family of triazine lead compounds."( Optimization of the pharmacokinetic properties of potent anti-trypanosomal triazine derivatives.
Augustyns, K; Baán, A; Caljon, G; Kiekens, F; Maes, L; Matheeussen, A; Salado, IG; Van der Veken, P; Verdeyen, T, 2018
)
0.48
" Data from three clinical studies, (i) eflornithine intravenous monotherapy, (ii) nifurtimox-eflornithine combination therapy, and (iii) eflornithine oral monotherapy, were pooled and analyzed using a time-to-event pharmacodynamic modeling approach, supported by in vitro activity data of the individual enantiomers."( Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy.
Äbelö, A; Amilon, C; Ashton, M; Boberg, M; Jansson-Löfmark, R; Tarning, J, 2022
)
0.95
" The pharmacokinetic (PK) information on nifurtimox in humans derived from controlled clinical studies is very limited."( Population Pharmacokinetics of Nifurtimox in Adult and Pediatric Patients With Chagas Disease.
Garmann, D; Hanze, E; Ince, I; Prins, K; Sadre-Marandi, F; Stass, H; Sutter, G; Willmann, S, 2022
)
1.27
" We investigated possible relationships between pharmacokinetic (PK) data, and pharmacodynamic efficacy and safety data collected in an analysis population of 111 participants in CHICO, using a published population PK model to estimate nifurtimox exposure at the patient level."( Nifurtimox for Treatment of Chagas Disease in Pediatric Patients: the Challenges of Applying Pharmacokinetic-Pharmacodynamic Principles to Dose Finding.
Grossmann, U; Ince, I; Stass, H; Weimann, B; Willmann, S, 2022
)
2.35

Compound-Compound Interactions

ExcerptReferenceRelevance
"The present work aimed to investigate the curative effect of benznidazole (BZL) in combination with other patented drugs [nifurtimox (NFX), posaconazole (POS) or AmBisome(®) (AMB)] in mice acutely or chronically infected with either a BZL-susceptible (Tulahuen) or a BZL-partially-resistant (Y) strain of Trypanosoma cruzi."( Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains.
Carlier, Y; Cencig, S; Coltel, N; Truyens, C, 2012
)
0.84

Bioavailability

ExcerptReferenceRelevance
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" These results, supported by the in silico prediction of a good oral bioavailability and a suitable risk profile, propose the 4-amino-7-chloroquinoline scaffold as a potential template for designing trypanocidal prototypes."( In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
Escario, JA; Fonseca-Berzal, C; Gómez-Barrio, A; Kouznetsov, VV; Rojas Ruiz, FA, 2014
)
0.4
" The present work reviews in detail the formulation and in-vitro/in-vivo analysis of different nanoformulations of nifurtimox and benznidazole in order to enhance their solubility, dissolution, bioavailability and trypanocidal activity."( Nanocarriers for effective delivery of benznidazole and nifurtimox in the treatment of chagas disease: A review.
Arrúa, EC; Bedogni, GR; Okulik, NB; Salomon, CJ; Seremeta, KP, 2019
)
0.97
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The introduction of the combination of nifurtimox and eflornithine (NECT) has accelerated the shift from melarsoprol to the best treatment available. The objective was to investigate and compare the population PK of nIfurimox in adult and pediatric patients with Chagas disease.

ExcerptRelevanceReference
" rhodesiense a single high dosage was more efficient than the same dose divided into many smaller applications."( The effect of nifurtimox on experimental infections with trypanosomatidae other than Trypanosoma cruzi.
Haberkorn, A, 1979
)
0.62
" Optimum dosage and duration of therapy, modes of administration and potential for large scale use are discussed."( Advances in sleeping sickness therapy.
Van Nieuwenhove, S, 1992
)
0.28
" These corresponded to 600 or 900 mg/day of allopurinol for 60 days and benznidazole or nifurtimox at conventional dosage regimens."( Therapeutic efficacy of allopurinol in patients with chronic Chagas' disease.
Gallerano, RH; Marr, JJ; Sosa, RR, 1990
)
0.5
" gambiense, but a daily dosage higher than 15 mg/kg/d will be necessary to achieve cure of most patients."( An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire.
Bruneel, H; DeGroof, D; Ethier, L; Meurice, F; Milord, F; Mpia, B; Pepin, J,
)
0.43
"At a dosage level of 8 to 10 mg/kg body-weight daily for 120 days nifurtimox was associated with clinical healing of cutaneous leishmaniasis in five of eight patients."( Further trials of nifurtimox in mucocutaneous leishmaniasis.
Barretto, AC; Cuba, CC; Guerra, MF; Marsden, PD, 1981
)
0.83
" Of 77 patients studied, 27 were treated with nifurtimox and 26 with benznidazole in the dosage of 5 m/kg/day for 30 consecutive days, and 24 received a placebo in tablets similar to benznidazole."( [Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation].
Coura, JR; de Abreu, LL; Petana, W; Willcox, HP,
)
0.63
" At the maximum dosage after 24 h of permanent contact with the cells (extreme, non-physiological conditions), cytolysis did not exceed 30%."( Action of new organometallic complexes against Leishmania donovani.
Craciunescu, D; Lazuen, J; Mesa-Valle, CM; Moraleda, V; Osuna, A, 1997
)
0.3
" The most used dosage schedules are: NFX for 60-90 days, 8-10 mg/kg/day in adults and < 15 mg/kg/day in children."( [Current prospects of specific treatment of Chagas' disease].
Coura, JR,
)
0.13
" At the end of dosing (40 weeks) and at the end of recovery (52 weeks), animals were sacrificed and subjected to complete gross and histopathological examinations, along with evaluations of body weight gain over time and terminal body weights."( Assessment of chronic toxicity and carcinogenicity in an accelerated cancer bioassay in rats of Nifurtimox, an antitrypanosomiasis drug.
Iatropoulos, MJ; von Keutz, E; Wang, CX; Williams, GM, 2006
)
0.55
" A combination chemotherapy, eflornithine alongside nifurtimox, has been introduced to decrease the time frame and overall dosing of eflornithine and reducing the risk of drug resistance emerging."( Potential new drugs for human African trypanosomiasis: some progress at last.
Barrett, MP, 2010
)
0.61
" However, a need for protracted and complicated drug dosing regimens slowed widespread implementation of eflornithine monotherapy."( Drug resistance in human African trypanosomiasis.
Barrett, MP; Burchmore, RJ; Kazibwe, AJ; Matovu, E; Vincent, IM, 2011
)
0.37
" The introduction of the combination of nifurtimox and eflornithine (NECT) has accelerated the shift from melarsoprol to the best treatment available, due to reduced dosage and treatment time for eflornithine that has significantly lessened the cost and improved the burden of logistics encountered during treatment and distribution."( Update on field use of the available drugs for the chemotherapy of human African trypanosomiasis.
Diarra, A; Franco, J; Jannin, J; Postigo, JA; Simarro, PP, 2012
)
0.65
" Exposure of parasites to the maximum concentrations of Compound 15 achieved in vivo with oral dosing yielded >2 logs of irreversible killing in <4 h, indicating rapid trypanocidal activity."( Pentacyclic nitrofurans that rapidly kill nifurtimox-resistant trypanosomes.
Bruhn, DF; Carrillo, AK; Fairlamb, AH; Guy, RK; Lee, RE; Rodríguez-Cortés, A; Wyllie, S, 2016
)
0.7
" We have adapted a continuous enzymatic assay to a medium-throughput format and carried out a primary screening of both collections, followed by construction and analysis of dose-response curves of the most promising hits."( Novel scaffolds for inhibition of Cruzipain identified from high-throughput screening of anti-kinetoplastid chemical boxes.
Agüero, F; Alvarez, VE; Cazzulo, JJ; Karpiak, J; Landaburu, LU; Madauss, KP; Salas-Sarduy, E, 2017
)
0.46
" Following initial profiling, a first proof-of-concept in vivo study was undertaken, in which once daily oral dosing of a 7-substituted 2-nitroimidazooxazine analogue suppressed blood parasitemia to low or undetectable levels, although sterile cure was not achieved."( Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
Avery, VM; Charman, SA; Chatelain, E; Cornwall, S; Denny, WA; Francisco, AF; Keenan, M; Kelly, JM; Marshall, AJ; O'Connor, PD; Perez, CJ; Read, KD; Riley, J; Sykes, ML; Thompson, AM; Thompson, RCA; White, KL; Zulfiqar, B, 2020
)
0.56
"Treatment of Chagas disease with nifurtimox requires age- and body weight-adjusted dosing, resulting in complex dosing instructions."( Biopharmaceutical Characteristics of Nifurtimox Tablets for Age- and Body Weight-Adjusted Dosing in Patients With Chagas Disease.
Altcheh, J; Feleder, E; Garcia-Bournissen, F; Nagelschmitz, J; Stass, H; Weimann, B; Yerino, G, 2021
)
1.18
"  We judged the study to be at low risk of bias in all domains except blinding;  as the route of administration and dosing regimens differed between treatment groups,  participants and personnel were not blinded, resulting in a high risk of performance bias."( Chemotherapy for second-stage human African trypanosomiasis: drugs in use.
Bergman, H; Lutje, V; Probyn, K; Seixas, J; Villanueva, G, 2021
)
0.62
" Standard dosing of eflornithine consists of repeated intravenous infusions of a racemic mixture of L- and D-eflornithine."( Population Pharmacodynamic Modeling of Eflornithine-Based Treatments Against Late-Stage Gambiense Human African Trypanosomiasis and Efficacy Predictions of L-eflornithine-Based Therapy.
Äbelö, A; Amilon, C; Ashton, M; Boberg, M; Jansson-Löfmark, R; Tarning, J, 2022
)
0.72
" The objective was to investigate and compare the population PK of nifurtimox in adult and pediatric patients with Chagas disease to confirm the clinical dosing regimen in children, which was based on allometric approaches using the concept that a dose-equivalent exposure would reach equivalent antiparasitic efficacy as in adults."( Population Pharmacokinetics of Nifurtimox in Adult and Pediatric Patients With Chagas Disease.
Garmann, D; Hanze, E; Ince, I; Prins, K; Sadre-Marandi, F; Stass, H; Sutter, G; Willmann, S, 2022
)
1.24
" Given the complex dosing regimen for nifurtimox, we also modeled nifurtimox exposure associated with simpler dosing strategies."( Nifurtimox for Treatment of Chagas Disease in Pediatric Patients: the Challenges of Applying Pharmacokinetic-Pharmacodynamic Principles to Dose Finding.
Grossmann, U; Ince, I; Stass, H; Weimann, B; Willmann, S, 2022
)
2.44
"This contemporary analysis of the complex metabolite profile and associated exposures emerging after oral dosing of nifurtimox in rats and humans, together with the expected low risk for clinically relevant DDIs, expands the understanding of this important anti-trypanosomal drug."(
Bairlein, M; Fricke, R; Gerisch, M; Lang, D; Schmuck, G; Schulz, SI; Stass, H, 2023
)
1.12
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
nitrofuran antibioticA member of the class of furans in which the furan ring is substituted by a nitro group and which also has significant antibiotic properties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency7.17670.000811.382244.6684AID686978
Cellular tumor antigen p53Homo sapiens (human)Potency1.43000.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
60 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)175.00000.17004.559010.0000AID1320592; AID1320594
Trypanothione reductaseTrypanosoma cruziKi245.00000.07605.15297.6000AID1459826
10 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)175.00000.17004.559010.0000AID1320592; AID1320594
60 kDa chaperonin Escherichia coliIC50 (µMol)175.00000.03903.55529.8000AID1320591; AID1320593
10 kDa chaperonin Escherichia coliIC50 (µMol)175.00000.03903.55529.8000AID1320591; AID1320593
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (153)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
adhesion of symbiont to host60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell mediated immune response to tumor cell60 kDa heat shock protein, mitochondrialHomo sapiens (human)
'de novo' protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to cold60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interferon-alpha production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-10 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-12 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-6 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein refolding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell proliferation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of macrophage activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
negative regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isotype switching to IgG isotypes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein stabilization60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone-mediated protein complex assembly60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein maturation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
biological process involved in interaction with symbiont60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cellular response to interleukin-760 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein import into mitochondrial intermembrane space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial unfolded protein response60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apoptotic mitochondrial changes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
osteoblast differentiation10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process10 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein10 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone cofactor-dependent protein refolding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (49)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
lipopolysaccharide binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
p53 binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
DNA replication origin binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
single-stranded DNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
double-stranded RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
high-density lipoprotein particle binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isomerase activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP hydrolysis activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
enzyme binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ubiquitin protein ligase binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein A-I binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP-dependent protein folding chaperone60 kDa heat shock protein, mitochondrialHomo sapiens (human)
RNA binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding chaperone10 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
metal ion binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (33)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytoplasm60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrion60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
early endosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytosol60 kDa heat shock protein, mitochondrialHomo sapiens (human)
plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
clathrin-coated pit60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cell surface60 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
coated vesicle60 kDa heat shock protein, mitochondrialHomo sapiens (human)
secretory granule60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm midpiece60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
migrasome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-containing complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
lipopolysaccharide receptor complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrion10 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane10 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome10 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix10 kDa heat shock protein, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (666)

Assay IDTitleYearJournalArticle
AID214152The compound was tested in vitro for antitrypanosomal activity against Trypanosoma cruzi epimastigotes at a dose of 25 uM1999Journal of medicinal chemistry, Jun-03, Volume: 42, Issue:11
1,2,5-Oxadiazole N-oxide derivatives and related compounds as potential antitrypanosomal drugs: structure-activity relationships.
AID1548444Antitrypanosomal activity against bloodstream form of wild type Trypanosoma brucei brucei S427 trypomastigotes assessed as inhibition of parasite growth
AID213632Evaluated in vitro for antitrypanosomal activity against Trypanosoma cruzi2002Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24
Antitrypanosomal activities and cytotoxicity of 5-nitro-2-furancarbohydrazides.
AID693360Growth inhibition of epimastigote form of Trypanosoma cruzi CL-B5 after 72 hrs by lacZ reporter gene assay2012European journal of medicinal chemistry, Dec, Volume: 58Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug.
AID1202573Anti-trypanosomal activity against Trypanosoma cruzi Silvio X10 cl1 epimastigote forms assessed as inhibition of parasite growth after 72 hrs by microplate reader based assay2015European journal of medicinal chemistry, , Volume: 96Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients.
AID1140953Mutagenic activity in Salmonella typhimurium TA98 at 0.5 to 30 ug/plate by Ames test in presence of mouse liver S9 fraction2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.
AID733451Trypanosomicidal activity against amastigote stage of Trypanosoma cruzi Tulahuen C4 transfected with beta-D-galactosidase infected in african green monkey Vero cells assessed as growth inhibition incubated 5 days prior to beta-D-galactopyranoside addition2013European journal of medicinal chemistry, Jan, Volume: 59Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates.
AID1422889Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi Dm28c epimastigotes infected in African green monkey Vero cells2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Discovery of a Biologically Active Bromodomain Inhibitor by Target-Directed Dynamic Combinatorial Chemistry.
AID548281Antimicrobial activity against Trypanosoma brucei NfxR12010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID1689522Selectivity index, ratio of EC50 for cytotoxicity against mouse J774 cells to EC50 for antitrypanosomal activity against bloodstream form Trypanosoma brucei brucei 4272020European journal of medicinal chemistry, Mar-01, Volume: 189Novel distamycin analogues that block the cell cycle of African trypanosomes with high selectivity and potency.
AID29360Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID303380Antitrypanosomal activity against Trypanosoma cruzi Y2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
In vivo anti-Chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives.
AID1695289Antileishmanial activity against amastigote form of Leishmania infantum MCAN_UY_2015_gPL8 isolate assessed as decrease in parasite viability measured after 72 hrs by resazurin assay2020RSC medicinal chemistry, Aug-01, Volume: 11, Issue:8
AID1740567Antitrypanosomal activity against bloodstream form of wild type Trypanosoma brucei brucei S427 trypomastigotes incubated for 72 hrs2020European journal of medicinal chemistry, Sep-15, Volume: 2028-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T. b. brucei and cruzi.
AID472700Antitrypanosomal activity against Trypanosoma cruzi tulahuen C4 trypomastigotes infected in african green monkey Vero cells assessed as CPRG cleavage after 120 hrs by microplate reader2010Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8
Trypanoside, anti-tuberculosis, leishmanicidal, and cytotoxic activities of tetrahydrobenzothienopyrimidines.
AID263384Antitrypanosomal activity against Trypanosoma cruzi amastigotes at 1 ug/ml2006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
New ligand-based approach for the discovery of antitrypanosomal compounds.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID362868Cytotoxicity against human THP1 cells after 48 hrs2008European journal of medicinal chemistry, May, Volume: 43, Issue:5
4-nitroacetophenone-derived thiosemicarbazones and their copper(II) complexes with significant in vitro anti-trypanosomal activity.
AID1202581Selectivity index, ratio of IC50 for Trypanosoma cruzi Bug 2149 cl10 to IC50 for Trypanosoma cruzi Y2015European journal of medicinal chemistry, , Volume: 96Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients.
AID447813Antitrypanosomal activity against Trypanosoma cruzi Y epimastigote form after 11 days by Trypan blue exclusion method2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Ruthenium complexes endowed with potent anti-Trypanosoma cruzi activity: Synthesis, biological characterization and structure-activity relationships.
AID1459829Cytotoxicity against human HeLa cells measured after 24 hrs by crystal violet staining based assay2017European journal of medicinal chemistry, Jan-05, Volume: 125Rational design of nitrofuran derivatives: Synthesis and valuation as inhibitors of Trypanosoma cruzi trypanothione reductase.
AID437131Toxicity in CD1 mouse lung at 300 mg/kg, ip after 3 days by histological study2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID252078Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 10 mg/mL after incubation for 48 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID437106Toxicity in CD1 mouse assessed as survival at 300 mg/kg, po after 3 days2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID1070006Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition at 2 uM after 7 days by beta-galactosidase reporter gene assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID353668Antiparasitic activity against Leishmania chagasi MHOM/BR/74/PP75 promastigotes infected in human THP1 cells after 72 hrs2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Synthesis and in vitro activity of new tetrahydronaphtho[1,2-b]azepine derivatives against Trypanosoma cruzi and Leishmania chagasi parasites.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1713345Antiprotozoal activity against wild type blood stream form of Trypanosoma brucei brucei assessed as growth inhibition incubated for 72 hrs followed by alamar blue addition further incubated for 16 hrs2016European journal of medicinal chemistry, Nov-10, Volume: 123Nitrotriazole-based acetamides and propanamides with broad spectrum antitrypanosomal activity.
AID248973In vitro inhibitory concentration against intracellular amastigotes of Trypanosoma cruzi in rat skeletal myoblasts incubated for 37 degree C for 4 days2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID1487116Antitrypanosomal activity against Trypanosoma cruzi Queretaro epimastigotes assessed as reduction in parasite viability incubated for 24 hrs by Neubauer hematocytometery2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis and biological evaluation of 2-methyl-1H-benzimidazole-5-carbohydrazides derivatives as modifiers of redox homeostasis of Trypanosoma cruzi.
AID392028Antitrypanosomal activity against Trypanosoma cruzi Argentinian isolate infected Swiss mouse assessed as inhibition of heart amastigote nests at 60 mg/kg/day, po2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
AID764117Selectivity index, ratio of IC50 for human FN1 fibroblasts to IC50 for epimastigotes of Trypanosoma cruzi Y2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
5-Nitro-2-furfuriliden derivatives as potential anti-Trypanosoma cruzi agents: design, synthesis, bioactivity evaluation, cytotoxicity and exploratory data analysis.
AID1399453Antitrypanosomal activity against Trypanosoma cruzi Tulahuen trypomastigote forms infected in monkey LLC-MK2 cells after 24 hrs by CellTiter-Glo luminescent cell viability assay2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Quinoxaline derivatives as potential antitrypanosomal and antileishmanial agents.
AID252079Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 10 mg/mL after incubation for 72 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID1575678Cytotoxicity against mouse J774 cells assessed as reduction in cell viability after 24 hrs by WST-1 assay2019MedChemComm, Aug-01, Volume: 10, Issue:8
Synthesis of bicyclic 1,4-thiazepines as novel anti-
AID1487118Selectivity index, ratio of CC50 for cytotoxicity against mouse J774 cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi Queretaro epimastigotes2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis and biological evaluation of 2-methyl-1H-benzimidazole-5-carbohydrazides derivatives as modifiers of redox homeostasis of Trypanosoma cruzi.
AID753034Cytotoxicity against human fibroblasts assessed as growth inhibition after 24 hrs by MTT assay2013European journal of medicinal chemistry, Jun, Volume: 64Ligand-based design, synthesis, and experimental evaluation of novel benzofuroxan derivatives as anti-Trypanosoma cruzi agents.
AID1811308Trypanocidal activity against Trypanosoma cruzi MHOM/MX/1994/Ninoa assessed as inhibition of parasite growth measured after 48 hrs by MTT assay2021Bioorganic & medicinal chemistry, 10-15, Volume: 48In vitro, ex vivo and in vivo short-term screening of DHEA nitrate derivatives activity over Trypanosoma cruzi Ninoa and TH strains from Oaxaca State, México.
AID463938Antiparasitic activity against Trypanosoma cruzi Tulahuen C4 infected african green monkey Vero cells expressing beta-galctosidase after 5 days2010Journal of natural products, Jan, Volume: 73, Issue:1
Dragonamide E, a modified linear lipopeptide from Lyngbya majuscula with antileishmanial activity.
AID1706435Antitrypanosomal activity against Trypanosoma cruzi Tulahuen strain C2C4 amastigotes infected in rat 3T3 cells assessed as reduction in parasite growth incubated for 48 hrs by chlorophenol red-fl-D-galactopyranoside based colorimetric analysis relative to2020European journal of medicinal chemistry, Dec-01, Volume: 207Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
AID491696Selectivity index, CC50 for african green monkey Vero cells to IC50 for Trypanosoma cruzi 320I01 epimastigote2010Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13
Synthesis, structural elucidation and in vitro antiparasitic activity against Trypanosoma cruzi and Leishmania chagasi parasites of novel tetrahydro-1-benzazepine derivatives.
AID525495Activity of Trypanosoma brucei NTR assessed as NADH oxidation per mg of protein at 100 uM2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Exploiting the drug-activating properties of a novel trypanosomal nitroreductase.
AID362867Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 after 5 days2008European journal of medicinal chemistry, May, Volume: 43, Issue:5
4-nitroacetophenone-derived thiosemicarbazones and their copper(II) complexes with significant in vitro anti-trypanosomal activity.
AID1333933Selectivity index, ratio of IC50 for cytotoxicity against mouse RAW264.7 cells to IC50 for antitrypanosomal activity against epimastigote stage of Trypanosoma cruzi Dm28c2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Synthesis, antioxidant and antichagasic properties of a selected series of hydroxy-3-arylcoumarins.
AID1272503Trypanocidal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes after 5 days2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Synthesis and biological evaluation of quinoxaline di-N-oxide derivatives with in vitro trypanocidal activity.
AID1333929Cytotoxicity against mouse RAW264.7 cells measured after 4 hrs by MTT assay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Synthesis, antioxidant and antichagasic properties of a selected series of hydroxy-3-arylcoumarins.
AID1486934Antiprotozoal activity against Leishmania amazonensis IFLA/BR/67/PH-8 incubated for 72 hrs by Neubauer chamber based cell counting method2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis, in vitro and in vivo giardicidal activity of nitrothiazole-NSAID chimeras displaying broad antiprotozoal spectrum.
AID1321005Antitrypanosomal activity against amastigote stage of Trypanosoma cruzi Y infected in human U2OS cells after 96 hrs by Draq5 staining-based high content screening assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Design, synthesis and antitrypanosomal activity of some nitrofurazone 1,2,4-triazolic bioisosteric analogues.
AID337145Antitrypanosomal activity against Trypanosoma cruzi 9280CL1 after 48 hrs
AID1406974Substrate activity at recombinant type-1 nitroreductase in bloodstream form of Trypanosoma brucei brucei S427 assessed as inhibition of parasite growth after 72 hrs2018European journal of medicinal chemistry, Sep-05, Volume: 1578-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent antitrypanosomatid molecules bioactivated by type 1 nitroreductases.
AID1140925Antitrypanosomal activity against Trypanosoma cruzi Sylvio X-10 amastigotes infected in African green monkey Vero cells assessed as eradication of amastigotes after 72 hrs by Giemsa staining-based assay2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.
AID337140Antitrypanosomal activity against Trypanosoma cruzi 13379 CL8 after 48 hrs
AID597209Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as growth inhibition at 25 uM after 5 days relative to control2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.
AID1319973Permeability of the compound by PAMPA assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.
AID1147556Antiprotozoal activity against Trypanosoma cruzi Y infected in CFW mouse assessed as increase in host mean survival time at 10 mg/kg, po administered daily for 10 days starting 4 hrs post-parasite infection1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID213961Growth inhibition of the intracellular Trypanosoma cruzi was measured by no. of parasites per 100 myoblasts (T. cruzi ) after 72 hr at the concentration of 1.0 (ug/mL)1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi.
AID548283Selectivity ratio of EC50 for Trypanosoma brucei NfxR1 to EC50 for Trypanosoma brucei2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID1186596Anti-trypanosomal activity against Trypanosoma brucei gambiense Feo bloodstream forms assessed as inhibition of parasite growth rate after 72 hrs by resazurin assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Synthesis of pyrazoline-thiazolidinone hybrids with trypanocidal activity.
AID214305Growth inhibition of the intracellular Trypanosoma cruzi was measured by counting percentage of myoblasts with Trypanosoma cruzi parasite after 48 hr (absence of compound)1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi.
AID213658In vitro anti protozoal activity against Trypanosoma cruzi strain Tulahuen CL2 was determined2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Biological evaluation of substituted quinolines.
AID1333934Antitrypanosomal activity against trypomastigote stage of Trypanosoma cruzi Dm28c infected in African green monkey Vero cells assessed as growth inhibition incubated for 5 to 7 days post infection measured after 24 hrs by MTT assay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Synthesis, antioxidant and antichagasic properties of a selected series of hydroxy-3-arylcoumarins.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1147562Antiprotozoal activity against high myocardial tissue infiltration leishmanial form of Trypanosoma cruzi BHC/10 infected in CFW mouse assessed as increase in host mean survival time at 10 mg/kg, po administered daily for 10 days starting 4 hrs post-parasi1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID337142Antitrypanosomal activity against Trypanosoma cruzi A98CL5 after 48 hrs
AID1596476Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei 90-13 reduction in parasite growth after 72 hrs by resazurin dye based fluorescence assay2019European journal of medicinal chemistry, Jul-15, Volume: 174Thiazolidinone/thiazole based hybrids - New class of antitrypanosomal agents.
AID1321006Cytotoxicity against human U2OS cells infected with amastigote stage of Trypanosoma cruzi Y assessed as decrease in number of cells after 96 hrs by Draq5 staining-based high content screening assay2016European journal of medicinal chemistry, Oct-04, Volume: 121Design, synthesis and antitrypanosomal activity of some nitrofurazone 1,2,4-triazolic bioisosteric analogues.
AID1754871Trypanocidal activity against Trypanosoma brucei brucei assessed as reduction in intracellular ATP production incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay2021Bioorganic & medicinal chemistry, 07-15, Volume: 42Synthesis and evaluation of trypanocidal activity of derivatives of naturally occurring 2,5-diphenyloxazoles.
AID333389Antitrypanosomal activity against extracellular Trypanosoma cruzi Tulahuen clone C42004Journal of natural products, Oct, Volume: 67, Issue:10
Novel cassane and cleistanthane diterpenes from Myrospermum frutescens: absolute stereochemistry of the cassane diterpene series.
AID1507198Selectivity index, ratio of IC50 for mouse NCTC-929 cells to IC50 for Trypanosoma cruzi clone CL B5 epimastigotes2017European journal of medicinal chemistry, Aug-18, Volume: 136Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.
AID1163253Trypanocidal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as parasite growth inhibition after 168 hrs by beta-galactosidase assay2014Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19
From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
AID263377Antitrypanosomal activity against Trypanosoma cruzi epimastigotes at 10 ug/ml2006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
New ligand-based approach for the discovery of antitrypanosomal compounds.
AID525499Cytotoxicity against human THP1 cells after 6 days by Alamar blue assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Exploiting the drug-activating properties of a novel trypanosomal nitroreductase.
AID477773Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 assessed as inhibition of epimastigotes growth at 50 uM2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Synthesis and in vitro activity of limonene derivatives against Leishmania and Trypanosoma.
AID253512Inhibitory concentration against wild-type (427) Trypanosoma brucei2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID396581Antitrypanosomal activity against Trypanosoma cruzi CL Brener epimastigotes2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Pyrimido[1,2-a]quinoxaline 6-oxide and phenazine 5,10-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi.
AID213958Growth inhibition of the intracellular Trypanosoma cruzi was measured by no. of parasites per 100 myoblasts (T. cruzi ) after 48 hr at the concentration of 5.0 (ug/mL)1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi.
AID710879Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi Y infected in LLC-MK2 cells assessed as parasite motility after 24 hrs2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.
AID473012Antiplasmodial activity against Plasmodium falciparum W2 by flow cytometry2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.
AID1742366Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID213956Growth inhibition of the intracellular Trypanosoma cruzi was measured by no. of parasites per 100 myoblasts (T. cruzi ) after 48 hr at the concentration of 1.0 (ug/mL)1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi.
AID1072681Cytotoxicity against BALB/c mouse splenocytes assessed as cell viability after 24 hrs by [3H]thymidine incorporation assay2014European journal of medicinal chemistry, Mar-21, Volume: 75Conformational restriction of aryl thiosemicarbazones produces potent and selective anti-Trypanosoma cruzi compounds which induce apoptotic parasite death.
AID393023Cytotoxicity against human HeLa cells after 24 hrs by MTT assay2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
New potent imidazoisoquinolinone derivatives as anti-Trypanosoma cruzi agents: biological evaluation and structure-activity relationships.
AID1070014Antimicrobial activity against epimastigote stage of Trypanosoma cruzi CL Brener assessed as growth inhibition after 72 hrs by beta-galactosidase reporter gene assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID343558Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi CL Brener2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle.
AID548287Antimicrobial activity against Trypanosoma brucei NfxR1 infected in NMRI mouse assessed as effect on parasitemia level at 100 mg/kg, ip QD for 3 days measured in 6 days by neubuaer hemocytometry2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID1706436Inhibition of Trypanosoma cruzi Tulahuen C4 strain CYP51 expressed in Escherichia coli by fluorescence based assay2020European journal of medicinal chemistry, Dec-01, Volume: 207Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
AID333387Antitrypanosomal activity against Trypanosoma cruzi Tulahuen CL2 by microdilution method2004Journal of natural products, Oct, Volume: 67, Issue:10
Triterpenoids from Brazilian Ilex species and their in vitro antitrypanosomal activity.
AID248819Inhibitory concentration in vitro against blood stream Trypanosoma brucei rhodesiense incubated for 72 hr at 37 degree C2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID710878Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Y infected in LLC-MK2 cells assessed as parasite motility after 11 days2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.
AID252072Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 1 mg/mL after incubation for 24 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID343557Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Tulahuen 22008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle.
AID486233Selectivity index, ratio of ID50 for mouse J774 cells to ID50 for Trypanosoma cruzi Tulahuen 22010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Naftifine-analogues as anti-Trypanosoma cruzi agents.
AID1264445Cytotoxicity against rat L6 cells after 6 days by resazurin staining based fluorescence plate reader assay2015European journal of medicinal chemistry, Nov-13, Volume: 105Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
AID1470751Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi INC-5 infected in NIH mouse blood assessed as parasite lysis at 50 ug/ml after 24 hrs by optical microscopic method relative to control2017European journal of medicinal chemistry, May-26, Volume: 132An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.
AID1147554Antiprotozoal activity against Trypanosoma cruzi BH infected in CFW mouse assessed as increase in host mean survival time at 5 mg/kg, po administered daily for 5 days starting 4 hrs post-parasite infection (Rvb = 14 +/- 1 days)1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID611498Antitrypanosomal activity against epimastigote forms of Trypanosoma cruzi CL-B5 transfected with Escherichia coli LacZ gene at 100 ug/ml after 72 hrs by chlorophenol red-Beta-D-galactopyranoside-based assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Ligand-based discovery of novel trypanosomicidal drug-like compounds: in silico identification and experimental support.
AID1300859Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei overexpressing type I nitroreductase assessed as inhibition of parasite growth after 3 days by resazurin assay in absence of tetracycline2016European journal of medicinal chemistry, Jul-19, Volume: 117Antitrypanosomal activity of 5-nitro-2-aminothiazole-based compounds.
AID324619Antitrypanosomal activity against Trypanosoma cruzi Tulahuen assessed as trypomastigote viability at 9.5 uM by MTT assay relative to control2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Trypanosoma cruzi: activities of lapachol and alpha- and beta-lapachone derivatives against epimastigote and trypomastigote forms.
AID565942Therapeutic index, ratio of IC50 for chinese hamster V79 cells to IC50 for Trypanosoma cruzi2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Trypanocidal activity of aziridinyl nitrobenzamide prodrugs.
AID1766402Selectivity index, ratio of IC50 for antileishmanial activity against wild type Leishmania donovani promastigotes to IC50 for antileishmanial activity against Leishmania donovani LdBOB derived from MHOM/SD/62/1 S-CL2D promastigotes overexpressing NTR12021ACS medicinal chemistry letters, Sep-09, Volume: 12, Issue:9
Monocyclic Nitro-heteroaryl Nitrones with Dual Mechanism of Activation: Synthesis and Antileishmanial Activity.
AID1507199Antitrypanosomal activity against Trypanosoma cruzi clone CL B5 amastigotes harboring lacZ infected in mouse NCTC-929 cells after 7 days by beta-galactosidase reporter gene assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.
AID1244576Antiparasitic activity against trypomastigotes of Trypanosoma cruzi Y assessed as reduction of parasite count after 24 hrs2015European journal of medicinal chemistry, Aug-28, Volume: 101Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.
AID447814Cytotoxicity against BALB/c mouse splenocytes after 24 hrs by [3H]thymidine incorporation assay2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Ruthenium complexes endowed with potent anti-Trypanosoma cruzi activity: Synthesis, biological characterization and structure-activity relationships.
AID449380Cytotoxicity against mouse J774 cells2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: synthesis, biological evaluation, and mode of action studies.
AID337139Antitrypanosomal activity against Trypanosoma cruzi 13379 CL6 after 48 hrs
AID764100Mutagenicity in Salmonella typhimurium TA98 at 0.5 to 30 ug/plate after 1 hr by Ames test in presence of S9 fraction2013European journal of medicinal chemistry, Aug, Volume: 66Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agents.
AID423032Antitrypanosomal activity against Trypanosoma cruzi at 16.9 uM2009Journal of natural products, Jan, Volume: 72, Issue:1
Antimalarial peptides from marine cyanobacteria: isolation and structural elucidation of gallinamide A.
AID252075Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 1 mg/mL after incubation for 98 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID477774Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 assessed as inhibition of epimastigotes growth2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
Synthesis and in vitro activity of limonene derivatives against Leishmania and Trypanosoma.
AID311103Cytotoxicity against human Vero cells by MTT assay2007Journal of natural products, Aug, Volume: 70, Issue:8
Hydroxyalkenylresorcinols from Stylogyne turbacensis.
AID396580Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Pyrimido[1,2-a]quinoxaline 6-oxide and phenazine 5,10-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi.
AID1147545Antiprotozoal activity against Trypanosoma cruzi BH infected in CFW mouse assessed as increase in host mean survival time at 50 mg/kg, ip administered daily for 5 days starting 4 hrs post-parasite infection (Rvb = 14 +/- 1 days)1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID753035Selectivity index, ratio of IC50 for human fibroblasts to GI50 for epimastigote stage of Trypanosoma cruzi Y2013European journal of medicinal chemistry, Jun, Volume: 64Ligand-based design, synthesis, and experimental evaluation of novel benzofuroxan derivatives as anti-Trypanosoma cruzi agents.
AID1351075Selectivity index, ratio of CC50 for cytotoxicity against human U2OS cells to IC50 for Trypanosoma cruzi Y Tc2 amastigotes infected in human U2OS cells2018European journal of medicinal chemistry, Jan-20, Volume: 144Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
AID105996Cytotoxicity in MRC-5 cells; ND = Not determined2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Biological evaluation of substituted quinolines.
AID313400Effect on oxygen redox cycling in Trypanosoma cruzi Y epimastigotes assessed as rate of oxygen consumption at 180 uM in presence of cyanide relative to control2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Heteroallyl-containing 5-nitrofuranes as new anti-Trypanosoma cruzi agents with a dual mechanism of action.
AID348153Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 22009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Synthesis, trypanocidal activity and docking studies of novel quinoxaline-N-acylhydrazones, designed as cruzain inhibitors candidates.
AID1202572Anti-trypanosomal activity against Trypanosoma cruzi Y epimastigote forms assessed as inhibition of parasite growth after 72 hrs by microplate reader based assay2015European journal of medicinal chemistry, , Volume: 96Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients.
AID525500Therapeutic index, ratio of IC50 against human THP1 cells to IC50 against Trypanosoma brucei2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Exploiting the drug-activating properties of a novel trypanosomal nitroreductase.
AID481119Antitrypanosomal activity against Trypanosoma cruzi Tulahuen infected in mouse 3T3 cells assessed as beta-galactosidase activity after 7 days by chagas bioassay2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Almiramides A-C: discovery and development of a new class of leishmaniasis lead compounds.
AID764119Cytotoxicity against mouse J774 cells after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
5-Nitro-2-furfuriliden derivatives as potential anti-Trypanosoma cruzi agents: design, synthesis, bioactivity evaluation, cytotoxicity and exploratory data analysis.
AID362673Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C4 in vero cells assessed as intracellular growth inhibition of trypomastigote by beta-galactosidase reporter gene assay2008Journal of natural products, Sep, Volume: 71, Issue:9
Viridamides A and B, lipodepsipeptides with antiprotozoal activity from the marine cyanobacterium Oscillatoria nigro-viridis.
AID1320592Inhibition of human mitochondrial HSP60/HSP10 expressed in Escherichia coli DH5alpha/BL21 (DE3) assessed as inhibition of denatured MDH refolding preincubated for 10 mins followed by ATP addition measured after 40 to 60 mins by fluorescence based assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.
AID525496Activity of Trypanosoma brucei NTR assessed as NADH oxidation2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Exploiting the drug-activating properties of a novel trypanosomal nitroreductase.
AID1429960Antitrypanosomal activity against Trypanosoma brucei 90-13 bloodstream forms after 72 hrs by CellTiter-Blue assay2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Antiparasitic lethality of sulfonamidebenzamides in kinetoplastids.
AID1383459Antitrypanosomal activity against Trypanosoma cruzi Sylvio X10/7 intracellular amastigotes forms assessed as reduction in number of amastigotes per host cell measured every 24 hrs for 96 hrs by time-kill assay2018European journal of medicinal chemistry, Apr-10, Volume: 149Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID337130Antitrypanosomal activity against Trypanosoma cruzi Tulahuen after 48 hrs
AID311099Antitrypanosomal activity against Trypanosoma cruzi2007Journal of natural products, Aug, Volume: 70, Issue:8
Hydroxyalkenylresorcinols from Stylogyne turbacensis.
AID597210Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as growth inhibition after 5 days2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.
AID1395365Antitrypanosomal activity against nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as reduction in parasite burden after 168 hrs by CPRG and Nonidet based spectrophotometric analysis2018European journal of medicinal chemistry, May-10, Volume: 151Optimization of the pharmacokinetic properties of potent anti-trypanosomal triazine derivatives.
AID1821416Trypanocidal activity against Trypanosoma brucei gambiense IL1922 assessed as parasite growth inhibition incubated for 3 days by Celltiter-Glo luminescence assay2022Journal of natural products, 01-28, Volume: 85, Issue:1
Benzophenone Glucosides and B-Type Proanthocyanidin Dimers from Zambian
AID1399456Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigote forms infected in rat H9c2 cells assessed as reduction in amastigote number per cell after 72 hrs by DRAQ5 DNA dye based confocal microscopic analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Quinoxaline derivatives as potential antitrypanosomal and antileishmanial agents.
AID1706426Antitrypanosomal activity against bloodstream trypomastigotes form of Trypanosoma cruzi CL Brener infected in BALB/c mouse assessed as reduction in parasitemia at 100 mg/kg, po qd administered for 5 days starting from day 114 post infection followed by cy2020European journal of medicinal chemistry, Dec-01, Volume: 207Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
AID1202575Cytotoxicity against human LL24 cells assessed as inhibition of cell growth after 24 hrs by MTT assay2015European journal of medicinal chemistry, , Volume: 96Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients.
AID733450Selectivity index, ratio of IC50 for mouse J774.1 cells to IC50 for amastigote stage of Trypanosoma cruzi Tulahuen C42013European journal of medicinal chemistry, Jan, Volume: 59Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates.
AID213963Growth inhibition of the intracellular Trypanosoma cruzi was measured by no. of parasites per 100 myoblasts (T. cruzi ) after 72 hr at the concentration of 5.0 (ug/mL)1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi.
AID1320591Inhibition of Escherichia coli GroEL/GroES expressed in Escherichia coli DH5alpha/BL21 (DE3) assessed as inhibition of denatured MDH refolding preincubated for 10 mins followed by ATP addition measured after 20 to 40 mins by fluorescence based assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.
AID337149Antitrypanosomal activity against Trypanosoma cruzi R107 after 48 hrs
AID337136Antitrypanosomal activity against Trypanosoma cruzi Z2CL4 after 48 hrs
AID1422885Antitrypanosomal activity against Trypanosoma cruzi Dm28c epimastigotes infected in African green monkey Vero cells after 72 hrs by CPRG/Nonidet reagent based beta-galactosidase reporter gene assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Discovery of a Biologically Active Bromodomain Inhibitor by Target-Directed Dynamic Combinatorial Chemistry.
AID437105Toxicity in CD1 mouse assessed as survival at 450 mg/kg, po after 3 days2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID1351069Antitrypanosomal activity against Trypanosoma cruzi Silvio X10 cl1 Tc1 epimastigotes measured after 72 hrs2018European journal of medicinal chemistry, Jan-20, Volume: 144Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
AID264013Trypanocidal activity against Trypanosoma brucei brucei after 48 hrs2006Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10
Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of Trypanosoma brucei as lead trypanocidal agents.
AID597216Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as cell death after 2 days by MTT assay2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.
AID252084Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 100 mg/mL after incubation for 72 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID439777Antitrypanosomal activity against Trypanosoma cruzi epimastigotes2009Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23
Neglected tropical diseases: multi-target-directed ligands in the search for novel lead candidates against Trypanosoma and Leishmania.
AID1140943Mutagenic activity in Salmonella typhimurium TA98 at 0.5 to 30 ug/plate by Ames test2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.
AID100892In vitro anti protozoal activity against Leishmania infantum strain MHOM-ET-67/L82 was determined; ND = Not determined2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Biological evaluation of substituted quinolines.
AID449385Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes after 5 days by MTT assay2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: synthesis, biological evaluation, and mode of action studies.
AID447812Antitrypanosomal activity against Trypanosoma cruzi Y trypomastigote form after 24 hrs by Trypan blue exclusion method2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Ruthenium complexes endowed with potent anti-Trypanosoma cruzi activity: Synthesis, biological characterization and structure-activity relationships.
AID482886Inhibition of Trypanosoma brucei rhodesiense recombinant rhodesain2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID1486932Antiprotozoal activity against Giardia intestinalis IMSS:0696:1 (genotype A) trophozoites incubated for 48 hrs2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis, in vitro and in vivo giardicidal activity of nitrothiazole-NSAID chimeras displaying broad antiprotozoal spectrum.
AID353667Antiparasitic activity against Trypanosoma cruzi 320I04 intracellular amastigotes infected in african green monkey Vero cells after 72 hrs2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Synthesis and in vitro activity of new tetrahydronaphtho[1,2-b]azepine derivatives against Trypanosoma cruzi and Leishmania chagasi parasites.
AID437116Toxicity in CD1 mouse assessed as hematocrite level at 450 mg/kg, po after 3 days2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID99863In vitro anti protozoal activity against Leishmania amazonensis strain MHOM/ET/L82/LV9 was determined; ND = Not determined2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Biological evaluation of substituted quinolines.
AID1754873Trypanocidal activity against Trypanosoma brucei rhodesiense assessed as reduction in intracellular ATP production incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay2021Bioorganic & medicinal chemistry, 07-15, Volume: 42Synthesis and evaluation of trypanocidal activity of derivatives of naturally occurring 2,5-diphenyloxazoles.
AID1586958Antitrypanosomal activity against Trypanosoma cruzi MHOM/BR/78/Silvio cloneX10/7A epimastigotes measured after 4 days by resazurin dye based fluorescence assay2019ACS medicinal chemistry letters, Jan-10, Volume: 10, Issue:1
Nongenotoxic 3-Nitroimidazo[1,2-
AID1187961Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for epimastigote stage of Trypanosoma cruzi2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
2-Phenylaminonaphthoquinones and related compounds: synthesis, trypanocidal and cytotoxic activities.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID324608Effect on oxygen redox cycling in Trypanosoma cruzi Tulahuen assessed as oxygen consumption per mg of protein relative to control2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Trypanosoma cruzi: activities of lapachol and alpha- and beta-lapachone derivatives against epimastigote and trypomastigote forms.
AID482884Inhibition of Trypanosoma brucei rhodesiense rhodesain after 12 hrs by fluorescence spectroscopy-based on-bead assay2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID248971Inhibitory concentration in vitro against intracellular amastigotes of Leishmania donovani in rat skeletal myoblasts incubated for 96 hr at 27 degree C2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID265556Antitrypanosomatid activity against Trypanosoma cruzi CL Brener epimastigote form2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
2H-benzimidazole 1,3-dioxide derivatives: a new family of water-soluble anti-trypanosomatid agents.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1202552Cytotoxicity against African green monkey Vero cells after 24 hrs by MTT assay2015European journal of medicinal chemistry, , Volume: 96Design, synthesis and biological evaluation of quinazoline derivatives as anti-trypanosomatid and anti-plasmodial agents.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1264443Inhibition of Electrophorus electricus acetylcholinesterase pre-incubated for 20 mins before acetylthiocholine iodide substrate addition by spectrophotometry2015European journal of medicinal chemistry, Nov-13, Volume: 105Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
AID1277398Antiparasitic activity against Trypanosoma cruzi Y trypomastigotes infected in rhesus monkey LLC-MK2 cells followed by re-infection of amastigotes in human U2OS cells assessed as reduction in parasite infection level after 96 hrs by draq5 staining based a2016European journal of medicinal chemistry, Feb-15, Volume: 109Highly improved antiparasitic activity after introduction of an N-benzylimidazole moiety on protein farnesyltransferase inhibitors.
AID1164929Trypanocidal activity against epimastigote forms of Trypanosoma cruzi Punta Lobos after 24 hrs2014European journal of medicinal chemistry, Nov-24, Volume: 87In vitro antiparasitic activity of new thiosemicarbazones in strains of Trypanosoma cruzi.
AID1399452Antitrypanosomal activity against Trypanosoma brucei Lister 427 bloodstream forms after 48 hrs by resazurin dye based fluorescence assay2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Quinoxaline derivatives as potential antitrypanosomal and antileishmanial agents.
AID1351068Antitrypanosomal activity against Trypanosoma cruzi Colombiana Tc1 epimastigotes measured after 72 hrs2018European journal of medicinal chemistry, Jan-20, Volume: 144Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
AID392029Antitrypanosomal activity against Trypanosoma cruzi Argentinian isolate infected Swiss mouse assessed as prevention of skeletal muscle inflammatory infiltrates at 60 mg/kg/day, po2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
AID437119Toxicity in CD1 mouse assessed as glutamic-pyruvate transaminase level at 300 mg/kg, ip after 3 days2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID1333930Antitrypanosomal activity against Trypanosoma cruzi Dm28c epimastigotes after 24 hrs by MTT assay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Synthesis, antioxidant and antichagasic properties of a selected series of hydroxy-3-arylcoumarins.
AID733447Ratio of nifurtimox IC50 to compound IC50 for axenic epimastigote stage of Trypanosoma cruzi Tulahuen 22013European journal of medicinal chemistry, Jan, Volume: 59Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates.
AID1740560Antileishmanial activity against Trypanosoma brucei brucei AnTat 1.9 measured after 74 hrs by Alamar blue assay2020European journal of medicinal chemistry, Sep-15, Volume: 2028-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T. b. brucei and cruzi.
AID1187958Trypanocidal activity against epimastigote stage of Trypanosoma cruzi infected in african green monkey Vero cells assessed as cell viability after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
2-Phenylaminonaphthoquinones and related compounds: synthesis, trypanocidal and cytotoxic activities.
AID353666Antiparasitic activity against Trypanosoma cruzi 320I04 epimastigotes infected in african green monkey Vero cells after 72 hrs2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Synthesis and in vitro activity of new tetrahydronaphtho[1,2-b]azepine derivatives against Trypanosoma cruzi and Leishmania chagasi parasites.
AID1689521Antitrypanosomal activity against bloodstream form Trypanosoma brucei brucei 427 infected in 449_Grx-roGFP2 cells assessed as cell viability after 24 hrs by propidium iodide staining based flow cytometric analysis2020European journal of medicinal chemistry, Mar-01, Volume: 189Novel distamycin analogues that block the cell cycle of African trypanosomes with high selectivity and potency.
AID1686726Genotoxicity in Salmonella typhimurium TA1535/pSK1002 in absence of rat S9 mix incubated for 4 hrs by SOS/umu test2016Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24
In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID548288Toxicity in NMRI mouse up to 200 mg/kg, ip QD daily for 3 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID1689528Selectivity ratio of EC50 for antitrypanosomal activity against bloodstream form Trypanosoma brucei brucei 427 assessed as cell viability after 24 hrs to antitrypanosomal activity against bloodstream form Trypanosoma brucei brucei 427 assessed as cell via2020European journal of medicinal chemistry, Mar-01, Volume: 189Novel distamycin analogues that block the cell cycle of African trypanosomes with high selectivity and potency.
AID1486933Antiprotozoal activity against Trichomonas vaginalis GT3 trophozoites incubated for 48 hrs2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis, in vitro and in vivo giardicidal activity of nitrothiazole-NSAID chimeras displaying broad antiprotozoal spectrum.
AID1406973Antileishmanial activity against wild type bloodstream form of Trypanosoma brucei brucei S427 after 72 hrs2018European journal of medicinal chemistry, Sep-05, Volume: 1578-Aryl-6-chloro-3-nitro-2-(phenylsulfonylmethyl)imidazo[1,2-a]pyridines as potent antitrypanosomatid molecules bioactivated by type 1 nitroreductases.
AID343556Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Tulahuen 2 at 25 uM relative to control2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle.
AID311101Cytotoxicity against human MCF7 cells2007Journal of natural products, Aug, Volume: 70, Issue:8
Hydroxyalkenylresorcinols from Stylogyne turbacensis.
AID1132881Antitrypanosomal activity against Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood at 52 mg/kg/day, intramuscular treatment started on day 10 of infection up to day 141977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
AID1067241Cytotoxicity against mouse J774 cells at 100 ug/mL after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Antiprotozoan lead discovery by aligning dry and wet screening: prediction, synthesis, and biological assay of novel quinoxalinones.
AID287713Antitrypanosomatid activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as reduction of growth after 5 days2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and structure-activity relationships.
AID1632141Antitrypanosomal activity against epimastigote forms of Trypanosoma cruzi NINOA isolated from chagas disease patient after 24 hrs by resazurin dye based spectrophotometric analysis2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Synthesis and trypanocidal activity of novel benzimidazole derivatives.
AID764112Selectivity index, ratio of IC50 for mouse J774 cells to IC50 for epimastigote form of Trypanosoma cruzi Tulahuen 22013European journal of medicinal chemistry, Aug, Volume: 66Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agents.
AID1486937Antiprotozoal activity against Trypanosoma cruzi MHOM/MX/1994/Ninoa incubated for 72 hrs by Neubauer chamber based cell counting method2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis, in vitro and in vivo giardicidal activity of nitrothiazole-NSAID chimeras displaying broad antiprotozoal spectrum.
AID1244577Cytotoxicity against BALB/c mouse splenocytes assessed as maximum non-toxic concentration by measuring [3H]-thymidine incorporation after 24 hrs by liquid scintillation counting2015European journal of medicinal chemistry, Aug-28, Volume: 101Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.
AID364959Antitrypanosomal activity against Trypanosoma cruzi Y assessed as parasite viability after 5 days by MTT assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
Furoxan-, alkylnitrate-derivatives and related compounds as anti-trypanosomatid agents: mechanism of action studies.
AID1429962Anti-parasitic activity against Leishmania amazonensis promastigotes after 44 hrs by CellTiter-Blue assay2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Antiparasitic lethality of sulfonamidebenzamides in kinetoplastids.
AID1070011Selectivity index, ratio of LC50 for mouse NCTC-929 cells to IC50 for epimastigote stage of Trypanosoma cruzi CL Brener2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID1147560Antiprotozoal activity against Trypanosoma cruzi Peru infected in CFW mouse assessed as increase in host mean survival time at 5 mg/kg, po administered daily for 10 days starting 4 hrs post-parasite infection1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID1399457Cytotoxicity against rat H9c2 cells infected with Trypanosoma cruzi Tulahuen amastigote forms assessed as reduction in cell number after 72 hrs by DRAQ5 DNA dye based confocal microscopic analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Quinoxaline derivatives as potential antitrypanosomal and antileishmanial agents.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID252077Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 10 mg/mL after incubation for 24 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID1548443Antitrypanosomal activity against blood stream form of Trypanosoma brucei brucei S427 trypomastigotes overexpressing NTR assessed as inhibition of parasite growth
AID482885Inhibition of Trypanosoma brucei rhodesiense recombinant rhodesain at 100 uM2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID565946Antitrypanosomal activity against Trypanosoma cruzi clone Cl-Brener infected in african green monkey Vero cells assessed as growth inhibition after 3 days by luciferase reporter gene assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Trypanocidal activity of aziridinyl nitrobenzamide prodrugs.
AID437129Toxicity in CD1 mouse heart at 300 mg/kg, ip after 3 days by histological study2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID1202574Anti-trypanosomal activity against Trypanosoma cruzi Bug 2149 cl10 epimastigote forms assessed as inhibition of parasite growth after 72 hrs by microplate reader based assay2015European journal of medicinal chemistry, , Volume: 96Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients.
AID214309Growth inhibition of the intracellular Trypanosoma cruzi was measured by counting percentage of myoblasts with Trypanosoma cruzi parasite after 72 hr at the concentration of 2.5 (ug/mL)1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi.
AID445551Antitrypanosomal activity against Trypanosoma cruzi CL Brener epimastigotes assessed as parasite viability after 5 days by MTT assay2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Anti-trypanosomatid benzofuroxans and deoxygenated analogues: synthesis using polymer-supported triphenylphosphine, biological evaluation and mechanism of action studies.
AID632306Antitrypanosomal activity against blood-stream Trypanosoma brucei brucei expressing type 1 nitroreductase after 3 days by alamar blue assay in absence of tetracycline2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents.
AID1632143Cytotoxicity against mouse J774 cells assessed as decrease in cell viability after 24 hrs by resazurin assay2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Synthesis and trypanocidal activity of novel benzimidazole derivatives.
AID264014Cytotoxicity against J774.1 cell line after 48 hrs2006Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10
Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of Trypanosoma brucei as lead trypanocidal agents.
AID1383461Trypanocidal activity against Trypanosoma cruzi Sylvio X10/7 intracellular amastigotes forms assessed as inhibition of maximum parasite growth measured every 24 hrs for 96 hrs by time-kill assay relative to control2018European journal of medicinal chemistry, Apr-10, Volume: 149Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID491697Antitrypanosomal activity against Trypanosoma cruzi 320I01 amastigotes infected in african green monkey Vero cells after 5 days by Giemsa staining2010Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13
Synthesis, structural elucidation and in vitro antiparasitic activity against Trypanosoma cruzi and Leishmania chagasi parasites of novel tetrahydro-1-benzazepine derivatives.
AID472699Cytotoxicity against african green monkey Vero cells after 72 hrs by MTS assay2010Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8
Trypanoside, anti-tuberculosis, leishmanicidal, and cytotoxic activities of tetrahydrobenzothienopyrimidines.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1507196Antitrypanosomal activity against Trypanosoma cruzi clone CL B5 epimastigotes at 25 uM after 72 hrs by beta-galactosidase reporter gene assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.
AID378804Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C4 infected in african green monkey Vero cells assessed as growth inhibition of trypomastigotes by beta-galactosidase reporter gene assay2006Journal of natural products, Oct, Volume: 69, Issue:10
Antiplasmodial metabolites isolated from the marine octocoral Muricea austera.
AID1740557Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 72 hrs by MTT assay2020European journal of medicinal chemistry, Sep-15, Volume: 2028-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T. b. brucei and cruzi.
AID1202549Antimicrobial activity against bloodstream trypomastigote stage of Trypanosoma cruzi NINOA after 24 hrs by Brener method2015European journal of medicinal chemistry, , Volume: 96Design, synthesis and biological evaluation of quinazoline derivatives as anti-trypanosomatid and anti-plasmodial agents.
AID1147563Antiprotozoal activity against high myocardial tissue infiltration leishmanial form of Trypanosoma cruzi BHC/10 infected in CFW mouse assessed as increase in host mean survival time at 5 mg/kg, po administered daily for 10 days starting 4 hrs post-parasit1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID548282Antimicrobial activity against Trypanosoma brucei NfxR22010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID1164930Trypanocidal activity against epimastigote forms of Trypanosoma cruzi Queretaro after 24 hrs2014European journal of medicinal chemistry, Nov-24, Volume: 87In vitro antiparasitic activity of new thiosemicarbazones in strains of Trypanosoma cruzi.
AID437117Toxicity in CD1 mouse assessed as hematocrite level at 300 mg/kg, ip after 3 days2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID1147544Antiprotozoal activity against Trypanosoma cruzi BH infected in CFW mouse assessed as increase in host mean survival time at 100 mg/kg, ip administered daily for 5 days starting 4 hrs post-parasite infection (Rvb = 14 +/- 1 days)1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID1706434Cytotoxicity against rat 3T3 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay2020European journal of medicinal chemistry, Dec-01, Volume: 207Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
AID1067243Trypanocidal activity against epimastigote stage of Trypanosoma cruzi CL Brener at 10 ug/mL after 72 hrs by beta-galactosidase reporter gene assay relative to control2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Antiprotozoan lead discovery by aligning dry and wet screening: prediction, synthesis, and biological assay of novel quinoxalinones.
AID525497Ratio of Kcat to Km for Trypanosoma brucei NTR2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Exploiting the drug-activating properties of a novel trypanosomal nitroreductase.
AID1399455Antitrypanosomal activity against Trypanosoma cruzi Tulahuen amastigote forms infected in rat H9c2 cells assessed as reduction in infected cells after 72 hrs by DRAQ5 DNA dye based confocal microscopic analysis2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Quinoxaline derivatives as potential antitrypanosomal and antileishmanial agents.
AID1351071Antitrypanosomal activity Trypanosoma cruzi Bug 2149 cl10 Tc5 epimastigotes measured after 72 hrs2018European journal of medicinal chemistry, Jan-20, Volume: 144Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
AID1165096Trypanocidal activity against bloodstream forms of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing type I nitroreductase assessed as inhibition of proliferation after 3 days by resazurin assay in presence of tetracycline2014European journal of medicinal chemistry, Nov-24, Volume: 87Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.
AID1140926Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi Sylvio X-10 amastigotes2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.
AID1821417Trypanocidal activity against Trypanosoma brucei rhodesiense IL1501 assessed as parasite growth inhibition incubated for 3 days by Celltiter-Glo luminescence assay2022Journal of natural products, 01-28, Volume: 85, Issue:1
Benzophenone Glucosides and B-Type Proanthocyanidin Dimers from Zambian
AID733446Ratio of nifurtimox IC50 to compound IC50 for amastigote stage of Trypanosoma cruzi Tulahuen C42013European journal of medicinal chemistry, Jan, Volume: 59Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates.
AID392035Toxicity against Trypanosoma cruzi infected CD1 mouse assessed as effect on kidney histology at 450 mg/kg, po2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
AID1507206Genotoxicity in Salmonella typhimurium TA98 at 3 to 10 ug/plate in absence of mouse liver S9 fraction by Ames test2017European journal of medicinal chemistry, Aug-18, Volume: 136Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.
AID391025Antitrypanosomal activity against Trypanosoma cruzi Tulahuen C4 in african green monkey Vero cells after 120 hrs2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Synthesis, cytotoxicity, and anti-Trypanosoma cruzi activity of new chalcones.
AID263379Unspecific cytotoxicity against murine J774 macrophages at 100 ug/ml2006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
New ligand-based approach for the discovery of antitrypanosomal compounds.
AID1575679Selectivity index, ratio of EC50 for mouse J774 cells to EC50 for antitrypanosomal activity against Trypanosoma brucei brucei 4272019MedChemComm, Aug-01, Volume: 10, Issue:8
Synthesis of bicyclic 1,4-thiazepines as novel anti-
AID437103Toxicity in CD1 mouse assessed as decrease in weight respect to day zero at 300 mg/kg, po after 3 days2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID1202551Antimicrobial activity against Leishmania mexicana MHOM/BZ/61/M379 after 24 hrs by haemocytometry2015European journal of medicinal chemistry, , Volume: 96Design, synthesis and biological evaluation of quinazoline derivatives as anti-trypanosomatid and anti-plasmodial agents.
AID1811312Selectivity index, ratio of CC50 for mouse J774.2 cells to IC50 for Trypanosoma cruzi ITRI/MX/2018/TH2021Bioorganic & medicinal chemistry, 10-15, Volume: 48In vitro, ex vivo and in vivo short-term screening of DHEA nitrate derivatives activity over Trypanosoma cruzi Ninoa and TH strains from Oaxaca State, México.
AID1132886Potency index, ratio of nifurtimox SD90 to compound SD90 for Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
AID1320596Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.
AID252082Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 100 mg/mL after incubation for 24 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID1320593Inhibition of Escherichia coli GroEL/GroES-ATPase activity expressed in Escherichia coli DH5alpha/BL21 (DE3) assessed as inhibition of denatured MDH refolding preincubated for 10 mins followed by ATP addition measured after 20 to 40 mins by malachite gree2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.
AID1140927Selectivity index, ratio of IC50 for human RBC to IC50 for Trypanosoma cruzi Sylvio X-10 amastigotes2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.
AID311100Antileishmanial activity against Leishmania donovani2007Journal of natural products, Aug, Volume: 70, Issue:8
Hydroxyalkenylresorcinols from Stylogyne turbacensis.
AID1277397Selectivity index, ratio of CC50 for human U2OS cells to EC50 for Trypanosoma cruzi Y amastigotes2016European journal of medicinal chemistry, Feb-15, Volume: 109Highly improved antiparasitic activity after introduction of an N-benzylimidazole moiety on protein farnesyltransferase inhibitors.
AID597213Antitrypanosomal activity against Trypanosoma cruzi CL Brener clone epimastigotes assessed as cell death after 2 days by MTT assay2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.
AID1811311Selectivity index, ratio of CC50 for mouse J774.2 cells to IC50 for Trypanosoma cruzi MHOM/MX/1994/Ninoa2021Bioorganic & medicinal chemistry, 10-15, Volume: 48In vitro, ex vivo and in vivo short-term screening of DHEA nitrate derivatives activity over Trypanosoma cruzi Ninoa and TH strains from Oaxaca State, México.
AID214310Growth inhibition of the intracellular Trypanosoma cruzi was measured by counting percentage of myoblasts with Trypanosoma cruzi parasite after 72 hr at the concentration of 5.0 (ug/mL)1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi.
AID1695291Antileishmanial activity against amastigote form of Leishmania infantum MCAN_UY_2015_gCH2 isolate assessed as decrease in parasite viability measured after 72 hrs by resazurin assay2020RSC medicinal chemistry, Aug-01, Volume: 11, Issue:8
AID362866Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 at 25 uM after 5 days2008European journal of medicinal chemistry, May, Volume: 43, Issue:5
4-nitroacetophenone-derived thiosemicarbazones and their copper(II) complexes with significant in vitro anti-trypanosomal activity.
AID1132885Antitrypanosomal activity against Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood intramuscularly treated daily from day 10 of infection up to day 141977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
AID396582Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes2008European journal of medicinal chemistry, Aug, Volume: 43, Issue:8
Pyrimido[1,2-a]quinoxaline 6-oxide and phenazine 5,10-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi.
AID158193In vitro anti-protozoal activity against Plasmodium falciparum W2; Not determined2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Biological evaluation of substituted quinolines.
AID1070012Cytotoxicity against mouse NCTC-929 cells after 48 hrs by resazurin staining-based fluorescence assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID700324Antitrypanosomal activity against Trypanosoma brucei bloodstream form overexpressing nitroreductase assessed as growth inhibition after 3 days by Alamar blue assay2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
Design, synthesis, and evaluation of potential prodrugs of DFMO for reductive activation.
AID1147548Antiprotozoal activity against Trypanosoma cruzi BH infected in CFW mouse assessed as increase in host mean survival time at 5 mg/kg, ip administered daily for 5 days starting 4 hrs post-parasite infection (Rvb = 14 +/- 1 days)1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID1162125Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for amastigote stage of Trypanosoma cruzi2014European journal of medicinal chemistry, Oct-30, Volume: 86Synthesis of novel polysubstituted (2SR,4RS)-2-heteroaryltetrahydro-1,4-epoxy-1-benzazepines and cis-2-heteroaryl-4-hydroxytetrahydro-1H-1-benzazepines as antiparasitic agents.
AID214308Growth inhibition of the intracellular Trypanosoma cruzi was measured by counting percentage of myoblasts with Trypanosoma cruzi parasite after 72 hr at the concentration of 1.0 (ug/mL)1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi.
AID1429959Cytotoxicity against human IMR90 cells after 44 to 46 hrs by CellTiter-Blue assay2017Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4
Antiparasitic lethality of sulfonamidebenzamides in kinetoplastids.
AID1361362Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi NINOA infected in NIH mouse blood assessed as parasite lysis at 10 ug/ml after 24 hrs by optical microscopic method relative to control2018European journal of medicinal chemistry, Aug-05, Volume: 156Synthesis, molecular docking and biological evaluation of novel phthaloyl derivatives of 3-amino-3-aryl propionic acids as inhibitors of Trypanosoma cruzi trans-sialidase.
AID1333935Selectivity index, ratio of IC50 for cytotoxicity against mouse RAW264.7 cells to IC50 for antitrypanosomal activity against trypomastigote stage of Trypanosoma cruzi Dm28c2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Synthesis, antioxidant and antichagasic properties of a selected series of hydroxy-3-arylcoumarins.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID392027Antitrypanosomal activity against Trypanosoma cruzi Argentinian isolate infected Swiss mouse assessed as prevention of heart inflammatory infiltrates at 60 mg/kg/day, po2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
AID693344Growth inhibition of epimastigote form of Trypanosoma cruzi CL-B5 at 64 uM after 72 hrs by lacZ reporter gene assay2012European journal of medicinal chemistry, Dec, Volume: 58Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug.
AID1264446Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei 2212015European journal of medicinal chemistry, Nov-13, Volume: 105Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1821418Trypanocidal activity against Trypanosoma brucei rhodesiense assessed as parasite growth inhibition incubated for 3 days by Celltiter-Glo luminescence assay2022Journal of natural products, 01-28, Volume: 85, Issue:1
Benzophenone Glucosides and B-Type Proanthocyanidin Dimers from Zambian
AID1300860Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei overexpressing type I nitroreductase assessed as inhibition of parasite growth after 3 days by resazurin assay in presence of tetracycline2016European journal of medicinal chemistry, Jul-19, Volume: 117Antitrypanosomal activity of 5-nitro-2-aminothiazole-based compounds.
AID364958Antitrypanosomal activity against Trypanosoma cruzi CL Brener assessed as parasite viability after 5 days by MTT assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
Furoxan-, alkylnitrate-derivatives and related compounds as anti-trypanosomatid agents: mechanism of action studies.
AID391027Selectivity index, IC50 for african green monkey Vero cells to IC50 for Trypanosoma cruzi Tulahuen C42008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Synthesis, cytotoxicity, and anti-Trypanosoma cruzi activity of new chalcones.
AID547618Antitrypanosomal activity against Trypanosoma cruzi CA-I/72 infected in BESM cells measured after 88 hrs postinfection by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID548286Antimicrobial activity against Trypanosoma brucei infected in NMRI mouse assessed as decrease in parasitemia level at 100 mg/kg, ip QD for 3 days measured after 30 days by neubuaer hemocytometry2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID449384Antitrypanosomal activity against Trypanosoma cruzi CL Brener epimastigotes after 5 days by MTT assay2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: synthesis, biological evaluation, and mode of action studies.
AID389018Antitrypanosomal activity against Trypanosoma cruzi2008Journal of natural products, Dec, Volume: 71, Issue:12
Antileishmanial constituents of the Panamanian endophytic fungus Edenia sp.
AID1361364Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi INC-5 infected in NIH mouse blood assessed as parasite lysis at 10 ug/ml after 24 hrs by optical microscopic method relative to control2018European journal of medicinal chemistry, Aug-05, Volume: 156Synthesis, molecular docking and biological evaluation of novel phthaloyl derivatives of 3-amino-3-aryl propionic acids as inhibitors of Trypanosoma cruzi trans-sialidase.
AID1072682Antitrypanosomal activity against Trypanosoma cruzi Y metacyclic trypomastigotes isolated from infected LLC-MK2 cells assessed as parasite viability after 24 hrs by neubauer chamber analysis2014European journal of medicinal chemistry, Mar-21, Volume: 75Conformational restriction of aryl thiosemicarbazones produces potent and selective anti-Trypanosoma cruzi compounds which induce apoptotic parasite death.
AID263383Antitrypanosomal activity against Trypanosoma cruzi amastigotes at 10 ug/ml2006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
New ligand-based approach for the discovery of antitrypanosomal compounds.
AID337137Antitrypanosomal activity against Trypanosoma cruzi 13379 CL3 after 48 hrs
AID449368Antitrypanosomal activity against Trypanosoma cruzi CL Brener epimastigotes assessed as parasitic cytotoxicity at 25 uM after 5 days by MTT assay2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: synthesis, biological evaluation, and mode of action studies.
AID1811310Cytotoxicity against mouse J774.2 cells assessed as reduction in cell viability measured after 48 hrs by resazurin dye based assay2021Bioorganic & medicinal chemistry, 10-15, Volume: 48In vitro, ex vivo and in vivo short-term screening of DHEA nitrate derivatives activity over Trypanosoma cruzi Ninoa and TH strains from Oaxaca State, México.
AID1067244Trypanocidal activity against epimastigote stage of Trypanosoma cruzi CL Brener at 100 ug/mL after 72 hrs by beta-galactosidase reporter gene assay relative to control2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Antiprotozoan lead discovery by aligning dry and wet screening: prediction, synthesis, and biological assay of novel quinoxalinones.
AID437113Toxicity in CD1 mouse assessed as leukocyte level at 300 mg/kg, ip after 3 days2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID597215Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as cell death at 10 uM after 2 days by MTT assay relative to control2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.
AID1132880Antitrypanosomal activity against Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood at 104 mg/kg/day, intramuscular treatment started on day 10 of infection up to day 141977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
AID392031Antitrypanosomal activity against Trypanosoma cruzi Argentinian isolate infected Swiss mouse assessed as prevention of liver congestion at 60 mg/kg/day, po2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
AID1319972Cytotoxicity against rat L6 cells after 6 days by resazurin based fluorescence assay2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.
AID1754874Trypanocidal activity against Trypanosoma congolense assessed as reduction in intracellular ATP production incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay2021Bioorganic & medicinal chemistry, 07-15, Volume: 42Synthesis and evaluation of trypanocidal activity of derivatives of naturally occurring 2,5-diphenyloxazoles.
AID1811309Trypanocidal activity against Trypanosoma cruzi ITRI/MX/2018/TH assessed as inhibition of parasite growth measured after 48 hrs by MTT assay2021Bioorganic & medicinal chemistry, 10-15, Volume: 48In vitro, ex vivo and in vivo short-term screening of DHEA nitrate derivatives activity over Trypanosoma cruzi Ninoa and TH strains from Oaxaca State, México.
AID437124Toxicity in CD1 mouse intestine at 450 mg/kg, po after 3 days by histological study2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID547619Antitrypanosomal activity against Trypanosoma cruzi Sylvio-X10/7 infected in BESM cells measured after 88 hrs postinfection by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID1713346Antiprotozoal activity against blood stream form of Trypanosoma brucei brucei assessed as growth inhibition expressing elevated level of type 1 nitroreductase incubated for 72 hrs followed by alamar blue addition further incubated for 16 hrs in presence o2016European journal of medicinal chemistry, Nov-10, Volume: 123Nitrotriazole-based acetamides and propanamides with broad spectrum antitrypanosomal activity.
AID1480082Antitrypanosomal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB 900 assessed as parasite growth inhibition after 72 hrs by Alamar blue assay2018Journal of medicinal chemistry, 04-26, Volume: 61, Issue:8
2 H-1,2,3-Triazole-Based Dipeptidyl Nitriles: Potent, Selective, and Trypanocidal Rhodesain Inhibitors by Structure-Based Design.
AID693345Growth inhibition of mouse J774 cells at 64 uM after 24 hrs by resazurin reduction assay2012European journal of medicinal chemistry, Dec, Volume: 58Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug.
AID263376Antitrypanosomal activity against Trypanosoma cruzi epimastigotes at 100 ug/ml2006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
New ligand-based approach for the discovery of antitrypanosomal compounds.
AID1695288Antileishmanial activity against amastigote form of Leishmania infantum MHOM/BR/2002/LPC-RPV assessed as decrease in parasite viability measured after 72 hrs by resazurin assay2020RSC medicinal chemistry, Aug-01, Volume: 11, Issue:8
AID1422887Antitrypanosomal activity against Trypanosoma cruzi Dm28c amastigotes infected in African green monkey Vero cells after 48 hrs by CPRG/Nonidet reagent based beta-galactosidase reporter gene assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Discovery of a Biologically Active Bromodomain Inhibitor by Target-Directed Dynamic Combinatorial Chemistry.
AID373861Antitrypanosomal activity against Trypanosoma cruzi SN3 trypomastigotes infected in african green monkey Vero cells assessed as parasite viability at 3.4 uM after 24 hrs by MTT assay2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Study of 5-nitroindazoles' anti-Trypanosoma cruzi mode of action: electrochemical behaviour and ESR spectroscopic studies.
AID565943Cytotoxicity against chinese hamster V79 cells after 6 days by Alamar blue assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Trypanocidal activity of aziridinyl nitrobenzamide prodrugs.
AID214303Growth inhibition of the intracellular Trypanosoma cruzi was measured by counting percentage of myoblasts with Trypanosoma cruzi parasite after 48 hr at the concentration of 2.5 (ug/mL)1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi.
AID1070004Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition at 0.5 uM after 7 days by beta-galactosidase reporter gene assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID473010Inhibition of Plasmodium falciparum recombinant falcipain-3 by standard fluorescence assay2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.
AID1309398Antitrypanosomal activity against epimastigote stage of Trypanosoma cruzi Tulahuen CL98 after 48 hrs by hemocytometry2016Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16
Novel drug design for Chagas disease via targeting Trypanosoma cruzi tubulin: Homology modeling and binding pocket prediction on Trypanosoma cruzi tubulin polymerization inhibition by naphthoquinone derivatives.
AID1162123Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for epimastigote stage of Trypanosoma cruzi2014European journal of medicinal chemistry, Oct-30, Volume: 86Synthesis of novel polysubstituted (2SR,4RS)-2-heteroaryltetrahydro-1,4-epoxy-1-benzazepines and cis-2-heteroaryl-4-hydroxytetrahydro-1H-1-benzazepines as antiparasitic agents.
AID744592Trypanocidal activity against Trypanosoma cruzi2013Bioorganic & medicinal chemistry letters, May-01, Volume: 23, Issue:9
New antiprotozoal agents: their synthesis and biological evaluations.
AID548279Antimicrobial activity against nifurtimox-resistant Trypanosoma brucei assessed as growth doubling time2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID392030Antitrypanosomal activity against Trypanosoma cruzi Argentinian isolate infected Swiss mouse assessed as inhibition of skeletal muscle amastigote nests at 60 mg/kg/day, po2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
AID264016Selectivity index, IC50 for J774.1/IC50 for Trypanosoma brucei brucei2006Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10
Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of Trypanosoma brucei as lead trypanocidal agents.
AID1147557Antiprotozoal activity against Trypanosoma cruzi Y infected in CFW mouse assessed as increase in host mean survival time at 5 mg/kg, po administered daily for 10 days starting 4 hrs post-parasite infection1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID287715Antitrypanosomatid activity against Trypanosoma cruzi Y epimastigotes assessed as reduction of growth after 5 days2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and structure-activity relationships.
AID482889Inhibition of human liver cathepsin B2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID1428311Antitrypanosomal activity against Trypanosoma brucei brucei 427 bloodstream forms infected CHO-K1 cells expressing redox biosensor hGrx-roGFP2 assessed as induction of hGrx-roGFP2 oxidation at 15 uM after 1 hr by flow cytometric method2017European journal of medicinal chemistry, Jan-27, Volume: 126In vitro activity and mode of action of distamycin analogues against African trypanosomes.
AID1507197Cytotoxicity against mouse NCTC-929 cells assessed as reduction in cell viability after 48 hrs by resazurin dye-based assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.
AID1320590Antitrypanosomal activity against Trypanosoma brucei brucei Lister 427 VSG 221 [TetR T7RNAP] transgenic bloodstream forms assessed as reduction in cell viability after 48 hrs by alamar blue assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.
AID1351073Antitrypanosomal activity against Trypanosoma cruzi Y Tc2 amastigotes infected in human U2OS cells after 72 hrs by Draq5 staining based HCS analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
AID1070007Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition at 4 uM after 7 days by beta-galactosidase reporter gene assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID611428Antitrypanosomal activity against amastigote forms of Trypanosoma cruzi CL-B5 expressing Escherichia coli LacZ gene infected in NCTC929 fibroblasts at 100 ug/ml after 7 days by chlorophenol red-Beta-D-galactopyranoside-based assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Ligand-based discovery of novel trypanosomicidal drug-like compounds: in silico identification and experimental support.
AID1507209Genotoxicity in Salmonella typhimurium TA98 up to 10 ug/plate in presence of mouse liver S9 fraction by Ames test2017European journal of medicinal chemistry, Aug-18, Volume: 136Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID213825Growth inhibition of the intracellular Trypanosoma cruzi was measured by counting no. of parasites per 100 myoblasts (T. cruzi ) after 48 hr (absence of compound)1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi.
AID1422886Antitrypanosomal activity against Trypanosoma cruzi Dm28c trypomastigotes infected in African green monkey Vero cells after 24 hrs by CPRG/Nonidet reagent based beta-galactosidase reporter gene assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Discovery of a Biologically Active Bromodomain Inhibitor by Target-Directed Dynamic Combinatorial Chemistry.
AID482887Antitrypanosomal activity against Trypanosoma brucei brucei2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID1631856Antitrypanosomal activity against Trypanosoma cruzi Y trypomastigotes infected in human HG39 cells after 48 hrs by RT-PCR assay2016Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16
Profiling of Flavonol Derivatives for the Development of Antitrypanosomatidic Drugs.
AID1496050Antitrypanosomal activity against Trypanosoma cruzi Silvio X10/7 intracellular forms2018Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11
Identification and preliminary structure-activity relationship studies of novel pyridyl sulfonamides as potential Chagas disease therapeutic agents.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID677571Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing tet-inducible NTR in presence of tetracycline after 3 days2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.
AID1428300Selectivity index, ratio of EC50 for murine macrophage J774 cells to EC50 for Trypanosoma brucei brucei 427 bloodstream forms2017European journal of medicinal chemistry, Jan-27, Volume: 126In vitro activity and mode of action of distamycin analogues against African trypanosomes.
AID1821411Trypanocidal activity against Trypanosoma brucei brucei GUTat3.1 assessed as parasite growth inhibition incubated for 3 days by Celltiter-Glo luminescence assay2022Journal of natural products, 01-28, Volume: 85, Issue:1
Benzophenone Glucosides and B-Type Proanthocyanidin Dimers from Zambian
AID1277396Cytotoxicity against human U2OS cells assessed as reduction in cell viability2016European journal of medicinal chemistry, Feb-15, Volume: 109Highly improved antiparasitic activity after introduction of an N-benzylimidazole moiety on protein farnesyltransferase inhibitors.
AID733449Trypanosomicidal activity against axenic epimastigote stage of Trypanosoma cruzi Tulahuen 2 assessed as growth inhibition2013European journal of medicinal chemistry, Jan, Volume: 59Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates.
AID1470753Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi NINOA infected in NIH mouse blood assessed as parasite lysis at 50 ug/ml after 24 hrs by optical microscopic method relative to control2017European journal of medicinal chemistry, May-26, Volume: 132An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.
AID611504Cytotoxicity against mouse J774 cells assessed as reduction in cell viability at 10 ug/ml after 24 hrs by resazurin-based colorimetric assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Ligand-based discovery of novel trypanosomicidal drug-like compounds: in silico identification and experimental support.
AID1422890Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi Dm28c trypomastigotes infected in African green monkey Vero cells2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Discovery of a Biologically Active Bromodomain Inhibitor by Target-Directed Dynamic Combinatorial Chemistry.
AID1162124Antiparasitic activity against amastigote stage of Trypanosoma cruzi infected in Vero cells assessed as parasite growth inhibition after 24 hrs by hemocytometery2014European journal of medicinal chemistry, Oct-30, Volume: 86Synthesis of novel polysubstituted (2SR,4RS)-2-heteroaryltetrahydro-1,4-epoxy-1-benzazepines and cis-2-heteroaryl-4-hydroxytetrahydro-1H-1-benzazepines as antiparasitic agents.
AID1695292Antileishmanial activity against amastigote form of Leishmania infantum MCAN_UY_2015_bCH11 isolate assessed as decrease in parasite viability measured after 72 hrs by resazurin assay2020RSC medicinal chemistry, Aug-01, Volume: 11, Issue:8
AID1740568Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei S427 trypomastigotes overexpressing NTR incubated for 72 hrs2020European journal of medicinal chemistry, Sep-15, Volume: 2028-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T. b. brucei and cruzi.
AID1459830Selectivity index, ratio of EC50 for cytotoxicity against human HeLa cells to IC50 for anti-parasitic activity against Trypanosoma cruzi Dm28c epimastigotes2017European journal of medicinal chemistry, Jan-05, Volume: 125Rational design of nitrofuran derivatives: Synthesis and valuation as inhibitors of Trypanosoma cruzi trypanothione reductase.
AID548285Antimicrobial activity against Trypanosoma brucei infected in NMRI mouse at 128 mg/kg, ip QD for 4 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID449381Selective index, ratio of ID50 for mouse J774 cells to ID50 for Trypanosoma cruzi Tulahuen 22009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: synthesis, biological evaluation, and mode of action studies.
AID1507190Growth inhibition of Trypanosoma cruzi clone CL B5 amastigotes harboring lacZ derived from infected mouse NCTC-929 cells at 25 uM after 7 days by beta-galactosidase reporter gene assay relative to control2017European journal of medicinal chemistry, Aug-18, Volume: 136Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.
AID1186598Selectivity index, ratio of CC50 for rat L6 cells to IC50 for Trypanosoma brucei gambiense Feo2014European journal of medicinal chemistry, Oct-06, Volume: 85Synthesis of pyrazoline-thiazolidinone hybrids with trypanocidal activity.
AID677267Antitrypanosomal activity against trypomastigote stage of Trypanosoma cruzi Dm28c at 10 umol/L after 24 hrs by MTT assay2012Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
Antitrypanosomal and antioxidant properties of 4-hydroxycoumarins derivatives.
AID1182899Trypanocidal activity against Trypanosoma cruzi Y epimastigotes infected in mouse J774 cells assessed as growth inhibition of parasite at 5 uM measured on day 52014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Synthesis and biological characterization of new aryloxyindole-4,9-diones as potent trypanosomicidal agents.
AID392006Toxicity against Trypanosoma cruzi infected CD1 mouse assessed as effect on heart histology at 450 mg/kg, po2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
AID106635Cytotoxicity in macrophages; ND = Not determined2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Biological evaluation of substituted quinolines.
AID214304Growth inhibition of the intracellular Trypanosoma cruzi was measured by counting percentage of myoblasts with Trypanosoma cruzi parasite after 48 hr at the concentration of 5.0 (ug/mL)1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi.
AID1459826Uncompetitive inhibition of Trypanosoma cruzi trypanothione reductase using T(SH)2 as substrate at pH 7.5 in presence of NADPH by photometric method2017European journal of medicinal chemistry, Jan-05, Volume: 125Rational design of nitrofuran derivatives: Synthesis and valuation as inhibitors of Trypanosoma cruzi trypanothione reductase.
AID373854Growth inhibition of Trypanosoma cruzi CL-Brener clone epimastigotes infected in mouse blood at 25 uM measured on day 5 postinfection by Brener method2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Study of 5-nitroindazoles' anti-Trypanosoma cruzi mode of action: electrochemical behaviour and ESR spectroscopic studies.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID437114Toxicity in CD1 mouse assessed as haemoglobin level at 450 mg/kg, po after 3 days2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID313390Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes after 48 hrs by MTT assay2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Heteroallyl-containing 5-nitrofuranes as new anti-Trypanosoma cruzi agents with a dual mechanism of action.
AID265553Antitrypanosomatid activity against Trypanosoma cruzi Tulahuen 2 epimastigote form at 25 uM2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
2H-benzimidazole 1,3-dioxide derivatives: a new family of water-soluble anti-trypanosomatid agents.
AID597223Cytotoxicity against mouse J774 cells2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.
AID1689527Antitrypanosomal activity against bloodstream form Trypanosoma brucei brucei 427 infected in 449_Grx-roGFP2 cells assessed as cell viability after 48 hrs by propidium iodide staining based flow cytometric analysis2020European journal of medicinal chemistry, Mar-01, Volume: 189Novel distamycin analogues that block the cell cycle of African trypanosomes with high selectivity and potency.
AID449391Antitrypanosomal activity against Trypanosoma cruzi Colombiana assessed as parasitic cytotoxicity at 25 uM after 5 days by MTT assay2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: synthesis, biological evaluation, and mode of action studies.
AID1245592Antiparasitic activity against blood stream form of Trypanosoma brucei brucei overexpressing type-1 nitroreductase after 3 days by Alamar blue assay in absence of tetracycline2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.
AID392033Toxicity against Trypanosoma cruzi infected CD1 mouse assessed as effect on liver histology at 450 mg/kg, po2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
AID215358In vitro anti protozoal activity against Trypanosoma brucei strain S427 was determined; ND = Not determined2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Biological evaluation of substituted quinolines.
AID1713347Antiprotozoal activity against blood stream form of Trypanosoma brucei brucei assessed as growth inhibition expressing elevated level of type 1 nitroreductase incubated for 72 hrs followed by alamar blue addition further incubated for 16 hrs2016European journal of medicinal chemistry, Nov-10, Volume: 123Nitrotriazole-based acetamides and propanamides with broad spectrum antitrypanosomal activity.
AID1245594Ratio of IC50 for blood stream form of Trypanosoma brucei brucei overexpressing type-1 nitroreductase in absence of tetracycline to IC50 for blood stream form of Trypanosoma brucei brucei overexpressing type-1 nitroreductase in presence of tetracycline2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.
AID1431504Anti-parasitic activity against Trypanosoma cruzi Y promastigotes infected in HG39 cells at 10 uM by qPCR analysis relative to control2017European journal of medicinal chemistry, Jan-27, Volume: 126Methoxylated 2'-hydroxychalcones as antiparasitic hit compounds.
AID1348368Antitrypanosomal activity against beta-galactosidase expressing nifurtimox-sensitive Trypanosoma cruzi Tulahuen CL2 infected in human MRC5 SV2 cells assessed as decrease in parasite burden after 168 hrs by spectrophotometric method2018European journal of medicinal chemistry, Jan-01, Volume: 143Novel triazine dimers with potent antitrypanosomal activity.
AID317676Growth inhibition of Trypanosoma cruzi epimastigotes Tulahuen 2 at 25 uM2008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Imidazolidines as new anti-Trypanosoma cruzi agents: biological evaluation and structure-activity relationships.
AID1348371Cytotoxicity against human MRC5 SV2 cells assessed as decrease in cell viability after 72 hrs by resazurin dye-based fluorometric method2018European journal of medicinal chemistry, Jan-01, Volume: 143Novel triazine dimers with potent antitrypanosomal activity.
AID1187960Cytotoxicity against african green monkey Vero cells by MTT assay2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
2-Phenylaminonaphthoquinones and related compounds: synthesis, trypanocidal and cytotoxic activities.
AID597212Antitrypanosomal activity against Trypanosoma cruzi CL Brener clone epimastigotes assessed as cell death at 10 uM after 2 days by MTT assay relative to control2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.
AID1072683Antitrypanosomal activity against Trypanosoma cruzi Dm28c epimastigotes assessed as inhibition of parasite proliferation after 5 days by hemocytometer analysis2014European journal of medicinal chemistry, Mar-21, Volume: 75Conformational restriction of aryl thiosemicarbazones produces potent and selective anti-Trypanosoma cruzi compounds which induce apoptotic parasite death.
AID693341Growth inhibition of mouse J774 cells at 256 uM after 24 hrs by resazurin reduction assay2012European journal of medicinal chemistry, Dec, Volume: 58Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug.
AID437126Toxicity in CD1 mouse kidney at 450 mg/kg, po after 3 days by histological study2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID548280Antimicrobial activity against Trypanosoma brucei2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID1742395Electrochemical behavior of the compound assessed as redox potential corrected toward saturated calomel electrode by cyclic voltammetry
AID1754875Trypanocidal activity against Trypanosoma evansi assessed as reduction in intracellular ATP production incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay2021Bioorganic & medicinal chemistry, 07-15, Volume: 42Synthesis and evaluation of trypanocidal activity of derivatives of naturally occurring 2,5-diphenyloxazoles.
AID214158Growth inhibition of the intracellular Trypanosoma cruzi was measured by counting percentage of myoblasts with Trypanosoma cruzi parasite after 24 hr (absence of compound)1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi.
AID437133Toxicity in CD1 mouse brain at 300 mg/kg, ip after 3 days by histological study2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID1487117Cytotoxicity against mouse J774 cells incubated for 24 hrs by resazurin dye based fluorescence assay2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis and biological evaluation of 2-methyl-1H-benzimidazole-5-carbohydrazides derivatives as modifiers of redox homeostasis of Trypanosoma cruzi.
AID710877Cytotoxicity against BALB/c mouse splenocytes assessed as highest nontoxic concentration by measuring [3H]-thymidine incorporation after 24 hrs by beta-radiation counting2012Journal of medicinal chemistry, Dec-27, Volume: 55, Issue:24
Structural investigation of anti-Trypanosoma cruzi 2-iminothiazolidin-4-ones allows the identification of agents with efficacy in infected mice.
AID1140928Selectivity index, ratio of IC50 for mouse J774.1 cells to IC50 for Trypanosoma cruzi Sylvio X-10 amastigotes2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.
AID611502Antitrypanosomal activity against amastigote forms of Trypanosoma cruzi CL-B5 expressing Escherichia coli LacZ gene infected in NCTC929 fibroblasts at 10 ug/ml after 7 days by chlorophenol red-Beta-D-galactopyranoside-based assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Ligand-based discovery of novel trypanosomicidal drug-like compounds: in silico identification and experimental support.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID597219Antitrypanosomal activity against Trypanosoma cruzi Colombiana epimastigotes assessed as cell death after 2 days by MTT assay2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.
AID449383Antitrypanosomal activity against Trypanosoma cruzi Colombiana after 5 days by MTT assay2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: synthesis, biological evaluation, and mode of action studies.
AID1667421Antitrypanosomal activity against Trypanosoma cruzi2020Bioorganic & medicinal chemistry letters, 04-15, Volume: 30, Issue:8
Discovery of 4-((1-(1H-imidazol-2-yl)alkoxy)methyl)pyridines as a new class of Trypanosoma cruzi growth inhibitors.
AID1264447Permeability of the compound by PAMPA method2015European journal of medicinal chemistry, Nov-13, Volume: 105Multicomponent reaction-based synthesis and biological evaluation of tricyclic heterofused quinolines with multi-trypanosomatid activity.
AID337150Antitrypanosomal activity against Trypanosoma cruzi TeCL2 after 48 hrs
AID1811313Antitrypanosomal activity against Trypanosoma cruzi MHOM/MX/1994/Ninoa infected in animal assessed as reduction in viable parasite in blood measured after 24 hrs by neubauer chamber assay2021Bioorganic & medicinal chemistry, 10-15, Volume: 48In vitro, ex vivo and in vivo short-term screening of DHEA nitrate derivatives activity over Trypanosoma cruzi Ninoa and TH strains from Oaxaca State, México.
AID253518Inhibitory concentration in vitro against blood stream Trypanosoma brucei brucei AT1 knockout mutant with a non functional P2 transporter; ND is not determined2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID473009Inhibition of Plasmodium falciparum recombinant falcipain-2 using Cbz-Leu-Arg-AMC as substrate by standard fluorescence assay2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.
AID1319975Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Trypanosoma brucei 221 bloodstream forms2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.
AID337141Antitrypanosomal activity against Trypanosoma cruzi C8 CL1 after 48 hrs
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1686727Genotoxicity in Salmonella typhimurium in presence of metabolic activation by SOS/umu test2016Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24
In Vitro and in Vivo Anti-Trypanosoma cruzi Activity of New Arylamine Mannich Base-Type Derivatives.
AID1383460Trypanocidal activity against Trypanosoma cruzi Sylvio X10/7 intracellular amastigotes forms measured every 24 hrs for 96 hrs by time-kill assay2018European journal of medicinal chemistry, Apr-10, Volume: 149Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: In vitro and in vivo evaluation, binding mode prediction and SAR exploration.
AID1182901Cytotoxicity against mouse J774 cells assessed as cell viability after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Synthesis and biological characterization of new aryloxyindole-4,9-diones as potent trypanosomicidal agents.
AID575180Antimicrobial activity against Trypanosoma cruzi infected in rat L6E9 myoblasts assessed as inhibition of [3H]uracil incorporation by giemsa staining2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Chemical validation of phosphodiesterase C as a chemotherapeutic target in Trypanosoma cruzi, the etiological agent of Chagas' disease.
AID1742371Antitrypanosomal activity against bloodstream form Trypanosoma brucei brucei AnTat 1.9 trypomastigotes assessed as reduction in parasite viability incubated for 69 hrs by Alamar Blue dye based assay
AID1202577Selectivity index, ratio of IC50 for human LL24 cells to IC50 for Trypanosoma cruzi Silvio X10 cl1 epimastigote forms2015European journal of medicinal chemistry, , Volume: 96Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients.
AID1147546Antiprotozoal activity against Trypanosoma cruzi BH infected in CFW mouse assessed as increase in host mean survival time at 25 mg/kg, ip administered daily for 5 days starting 4 hrs post-parasite infection (Rvb = 14 +/- 1 days)1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID353672Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for Trypanosoma cruzi 320I04 intracellular amastigotes2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Synthesis and in vitro activity of new tetrahydronaphtho[1,2-b]azepine derivatives against Trypanosoma cruzi and Leishmania chagasi parasites.
AID353671Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for Trypanosoma cruzi 320I04 epimastigotes2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Synthesis and in vitro activity of new tetrahydronaphtho[1,2-b]azepine derivatives against Trypanosoma cruzi and Leishmania chagasi parasites.
AID1165097Ratio of IC50 for bloodstream forms of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing type I nitroreductase in absence of tetracycline to IC50 for bloodstream forms of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing type I n2014European journal of medicinal chemistry, Nov-24, Volume: 87Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.
AID700327Ratio of IC50 for wild type Trypanosoma brucei bloodstream form to IC50 for Trypanosoma brucei bloodstream form overexpressing nitroreductase2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
Design, synthesis, and evaluation of potential prodrugs of DFMO for reductive activation.
AID214302Growth inhibition of the intracellular Trypanosoma cruzi was measured by counting percentage of myoblasts with Trypanosoma cruzi parasite after 48 hr at the concentration of 1.0 (ug/mL)1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi.
AID764122Antitrypanosomal activity against epimastigotes of Trypanosoma cruzi Y assessed as parasite growth inhibition after 5 days by spectrophotometric analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
5-Nitro-2-furfuriliden derivatives as potential anti-Trypanosoma cruzi agents: design, synthesis, bioactivity evaluation, cytotoxicity and exploratory data analysis.
AID337135Antitrypanosomal activity against Trypanosoma cruzi Z2 after 48 hrs
AID445550Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as parasite growth inhibition after 5 days2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Anti-trypanosomatid benzofuroxans and deoxygenated analogues: synthesis using polymer-supported triphenylphosphine, biological evaluation and mechanism of action studies.
AID253516In vitro inhibitory concentration against blood stream Trypanosoma brucei brucei AT1 wild type incubated for 72 h at 37 degree C2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID753036Antitrypanosomal activity against epimastigote stage of Trypanosoma cruzi Y assessed as parasite growth inhibition after 5 days by spectrophotometric analysis2013European journal of medicinal chemistry, Jun, Volume: 64Ligand-based design, synthesis, and experimental evaluation of novel benzofuroxan derivatives as anti-Trypanosoma cruzi agents.
AID449387Inhibition of Mitochondrial dehydrogenase in Trypanosoma cruzi Y epimastigotes at 20 uM after 30 to 240 mins by MTT dye reduction assay in relative to control2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: synthesis, biological evaluation, and mode of action studies.
AID611500Antitrypanosomal activity against epimastigote forms of Trypanosoma cruzi CL-B5 transfected with Escherichia coli beta-galactosidase gene LacZ at 1 ug/ml after 72 hrs by chlorophenol red-Beta-D-galactopyranoside-based assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Ligand-based discovery of novel trypanosomicidal drug-like compounds: in silico identification and experimental support.
AID693343Growth inhibition of mouse J774 cells at 128 uM after 24 hrs by resazurin reduction assay2012European journal of medicinal chemistry, Dec, Volume: 58Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug.
AID677572Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing tet-inducible NTR in absence of tetracycline after 3 days2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.
AID1592306Selectivity index, ratio of CC50 for mouse J774.A1 cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi MHOM/MX/1994/INC5 epimastigotes
AID392034Toxicity against Trypanosoma cruzi infected CD1 mouse assessed as effect on heart histology at 300 mg/kg, ip2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
AID1592304Cytotoxicity against mouse J774.A1 cells assessed as reduction in cell viability measured after 20 hrs by MTT assay
AID437122Toxicity in CD1 mouse assessed as glutamic-oxalacetate transaminase level at 300 mg/kg, ip after 3 days2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID1070015Antimicrobial activity against epimastigote stage of Trypanosoma cruzi CL Brener assessed as growth inhibition at 256 uM after 72 hrs by beta-galactosidase reporter gene assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1428308Antitrypanosomal activity against Trypanosoma brucei brucei 427 bloodstream forms assessed as induction of membrane permeabilization at 15 uM after 0.5 to 4 hrs by propidium iodide dye based flow cytometry2017European journal of medicinal chemistry, Jan-27, Volume: 126In vitro activity and mode of action of distamycin analogues against African trypanosomes.
AID1202578Selectivity index, ratio of IC50 for human LL24 cells to IC50 for Trypanosoma cruzi Bug 2149 cl102015European journal of medicinal chemistry, , Volume: 96Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients.
AID1821420Trypanocidal activity against Trypanosoma evansi assessed as parasite growth inhibition incubated for 3 days by Celltiter-Glo luminescence assay2022Journal of natural products, 01-28, Volume: 85, Issue:1
Benzophenone Glucosides and B-Type Proanthocyanidin Dimers from Zambian
AID437115Toxicity in CD1 mouse assessed as haemoglobin level at 300 mg/kg, ip after 3 days2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID1196731Cytotoxicity against mouse L929 cells assessed as metabolic activity at 100 uM after 48 hrs by Alamar Blue assay relative to untreated control2015European journal of medicinal chemistry, Mar-06, Volume: 92Antileishmanial activity of quinazoline derivatives: synthesis, docking screens, molecular dynamic simulations and electrochemical studies.
AID677575Selectivity ratio of IC50 for Trypanosoma brucei brucei Lister 427 clone 221a overexpressing tet-inducible NTR in presence of tetracycline to IC50 for Trypanosoma brucei brucei overexpressing tet-inducible NTR in absence of tetracyclin2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.
AID1245593Antiparasitic activity against blood stream form of Trypanosoma brucei brucei overexpressing type-1 nitroreductase after 3 days by Alamar blue assay in presence of tetracycline2015Bioorganic & medicinal chemistry, Oct-01, Volume: 23, Issue:19
Discovery of potent nitrotriazole-based antitrypanosomal agents: In vitro and in vivo evaluation.
AID1351070Antitrypanosomal activity Trypanosoma cruzi Y Tc2 epimastigotes measured after 72 hrs2018European journal of medicinal chemistry, Jan-20, Volume: 144Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
AID252074Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 1 mg/mL after incubation for 72 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID1695293Antileishmanial activity against amastigote form of Leishmania infantum MCAN_UY_2015_mCO8 isolate assessed as decrease in parasite viability measured after 72 hrs by resazurin assay2020RSC medicinal chemistry, Aug-01, Volume: 11, Issue:8
AID437107Toxicity in CD1 mouse assessed as decrease in weight respect to day zero at 300 mg/kg, ip after 3 days2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID392032Toxicity against Trypanosoma cruzi infected CD1 mouse assessed as effect on liver histology at 300 mg/kg, ip2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
AID1592303Antitrypanosomal activity against Trypanosoma cruzi MHOM/MX/1994/INC5 epimastigotes assessed as growth inhibition measured after 24 hrs by MTT assay
AID1351072Antitrypanosomal activity against Trypanosoma cruzi Colombiana Tc1 trypamastigotes infected in monkey LLC-MK2 cells assessed as inhibition of parasite viability by measuring motility at 1 uM after 20 hrs by light microscopic method relative to control2018European journal of medicinal chemistry, Jan-20, Volume: 144Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
AID548299Drug level in serum of patient with human african trypanosomiasis at 15 mg/kg, po administered every 8 hrs for 10 days2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID1186597Cytotoxicity against rat L6 cells after 5 days by resazurin assay2014European journal of medicinal chemistry, Oct-06, Volume: 85Synthesis of pyrazoline-thiazolidinone hybrids with trypanocidal activity.
AID213824Growth inhibition of the intracellular Trypanosoma cruzi was measured by counting no. of parasites per 100 myoblasts (T. cruzi ) after 24 h (absence of compound)1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi.
AID1244575Antiparasitic activity against epimastigotes of Trypanosoma cruzi Dm28c assessed as reduction of parasite count after 5 days2015European journal of medicinal chemistry, Aug-28, Volume: 101Synthesis and structure-activity relationship study of a new series of antiparasitic aryloxyl thiosemicarbazones inhibiting Trypanosoma cruzi cruzain.
AID213962Growth inhibition of the intracellular Trypanosoma cruzi was measured by no. of parasites per 100 myoblasts (T. cruzi ) after 72 hr at the concentration of 2.5 (ug/mL)1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi.
AID494147Octanol-water partition coefficient of the compound2010Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16
Anti-T. cruzi activities and QSAR studies of 3-arylquinoxaline-2-carbonitrile di-N-oxides.
AID597218Antitrypanosomal activity against Trypanosoma cruzi Colombiana epimastigotes assessed as cell death at 10 uM after 2 days by MTT assay relative to control2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.
AID1067239Cytotoxicity against mouse J774 cells at 1 ug/mL after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Antiprotozoan lead discovery by aligning dry and wet screening: prediction, synthesis, and biological assay of novel quinoxalinones.
AID1470752Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi INC-5 infected in NIH mouse blood after 24 hrs by optical microscopic method2017European journal of medicinal chemistry, May-26, Volume: 132An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID303378Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 22007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
In vivo anti-Chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives.
AID252085Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 100 mg/mL after incubation for 98 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID1182902Selectivity index, ratio of IC50 for mouse J774A cells to IC50 for Trypanosoma cruzi Y epimastigotes2014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Synthesis and biological characterization of new aryloxyindole-4,9-diones as potent trypanosomicidal agents.
AID264010Inhibition of Trypanosoma brucei rhodesiense rhodesain2006Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10
Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of Trypanosoma brucei as lead trypanocidal agents.
AID263380Unspecific cytotoxicity against murine J774 macrophages at 10 ug/ml2006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
New ligand-based approach for the discovery of antitrypanosomal compounds.
AID449369Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as inhibition of parasite growth after 5 days2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: synthesis, biological evaluation, and mode of action studies.
AID364956Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 assessed as inhibition of epimastigotes growth after 5 days by MTT assay relative to control2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
Furoxan-, alkylnitrate-derivatives and related compounds as anti-trypanosomatid agents: mechanism of action studies.
AID1070003Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition after 7 days by beta-galactosidase reporter gene assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID1070008Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition at 8 uM after 7 days by beta-galactosidase reporter gene assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID764113Cytotoxicity against mouse J774 cells assessed as cell viability after 48 hrs by MTT assay2013European journal of medicinal chemistry, Aug, Volume: 66Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agents.
AID437125Toxicity in CD1 mouse intestine at 300 mg/kg, ip after 3 days by histological study2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID733448Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for amastigote stage of Trypanosoma cruzi Tulahuen C42013European journal of medicinal chemistry, Jan, Volume: 59Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates.
AID324607Effect on oxygen uptake per mg of protein in Trypanosoma cruzi Tulahuen epimastigotes relative to control2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Trypanosoma cruzi: activities of lapachol and alpha- and beta-lapachone derivatives against epimastigote and trypomastigote forms.
AID1320595Cytotoxicity against human THLE3 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.
AID356065Antitrypanosomal activity against Trypanosoma cruzi epimastigotes after 3 days2003Journal of natural products, Jul, Volume: 66, Issue:7
Five new cassane diterpenes from Myrospermum frutescens with activity against Trypanosoma cruzi.
AID437132Toxicity in CD1 mouse brain at 450 mg/kg, po after 3 days by histological study2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID356066Antitrypanosomal activity against Trypanosoma cruzi Tulahuen clone C4 trypomastigotes in HFF after 7 days by beta-galactosidase reporter gene assay2003Journal of natural products, Jul, Volume: 66, Issue:7
Five new cassane diterpenes from Myrospermum frutescens with activity against Trypanosoma cruzi.
AID693340Growth inhibition of epimastigote form of Trypanosoma cruzi CL-B5 at 128 uM after 72 hrs by lacZ reporter gene assay2012European journal of medicinal chemistry, Dec, Volume: 58Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug.
AID337146Antitrypanosomal activity against Trypanosoma cruzi CL after 48 hrs
AID437120Toxicity in CD1 mouse assessed as glutamic-oxalacetate transaminase level at 450 mg/kg, po after 3 days2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID1070013Cytotoxicity against mouse NCTC-929 cells at 256 uM after 48 hrs by resazurin staining-based fluorescence assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID1496051Cytotoxic activity against African green monkey Vero cells2018Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11
Identification and preliminary structure-activity relationship studies of novel pyridyl sulfonamides as potential Chagas disease therapeutic agents.
AID601427Antichagasic activity against Trypanosoma cruzi Tulahuen 22011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
In search of patterns over physicochemical properties and pharmacological activities for a set of [MCl₂(thiosemicarbazone)] complexes (M=Pt/Pd): support for multiple mechanisms of antichagasic action excluding DNA-bonding in vivo?
AID1202582Selectivity index, ratio of IC50 for Trypanosoma cruzi Silvio X10 cl1 to IC50 for Trypanosoma cruzi Y2015European journal of medicinal chemistry, , Volume: 96Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients.
AID437127Toxicity in CD1 mouse kidney at 300 mg/kg, ip after 3 days by histological study2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID1821419Trypanocidal activity against Trypanosoma brucei congolense IL3000 assessed as parasite growth inhibition incubated for 3 days by Celltiter-Glo luminescence assay2022Journal of natural products, 01-28, Volume: 85, Issue:1
Benzophenone Glucosides and B-Type Proanthocyanidin Dimers from Zambian
AID1182900Trypanocidal activity against Trypanosoma cruzi Y epimastigotes infected in mouse J774 cells assessed as growth inhibition of parasite measured on day 52014Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16
Synthesis and biological characterization of new aryloxyindole-4,9-diones as potent trypanosomicidal agents.
AID1147558Antiprotozoal activity against Trypanosoma cruzi Peru infected in CFW mouse assessed as increase in host mean survival time at 25 mg/kg, po administered daily for 10 days starting 4 hrs post-parasite infection1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID437123Toxicity in CD1 mouse liver at 450 mg/kg, po after 3 days by histological study2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID611505Cytotoxicity against mouse J774 cells assessed as reduction in cell viability at 1 ug/ml after 24 hrs by resazurin-based colorimetric assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Ligand-based discovery of novel trypanosomicidal drug-like compounds: in silico identification and experimental support.
AID213957Growth inhibition of the intracellular Trypanosoma cruzi was measured by no. of parasites per 100 myoblasts (T. cruzi ) after 48 hr at the concentration of 2.5 (ug/mL)1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi.
AID324605Growth inhibition of Trypanosoma cruzi Tulahuen epimastigotes assessed as drug level causing decrease in growth constant2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Trypanosoma cruzi: activities of lapachol and alpha- and beta-lapachone derivatives against epimastigote and trypomastigote forms.
AID764118Cytotoxicity against human FN1 fibroblasts after 24 hrs by MTT assay2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
5-Nitro-2-furfuriliden derivatives as potential anti-Trypanosoma cruzi agents: design, synthesis, bioactivity evaluation, cytotoxicity and exploratory data analysis.
AID362869Therapeutic index, ID50 for human THP1 cells to ID50 for Trypanosoma cruzi2008European journal of medicinal chemistry, May, Volume: 43, Issue:5
4-nitroacetophenone-derived thiosemicarbazones and their copper(II) complexes with significant in vitro anti-trypanosomal activity.
AID1705623Antitrypanosomal activity against bloodstream form of Trypanosoma brucei brucei assessed as parasite growth inhibition incubated for 3 days by alamar blue staining based assay2020European journal of medicinal chemistry, Dec-01, Volume: 207Design, synthesis, antitrypanosomal activity, DNA/RNA binding and in vitro ADME profiling of novel imidazoline-substituted 2-arylbenzimidazoles.
AID781031Trypanocidal activity against bloodstream forms of Trypanosoma brucei brucei Lister 427 clone 221a after 72 hrs by AlamarBlue assay2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Synthesis and anti-parasitic activity of a novel quinolinone-chalcone series.
AID337132Antitrypanosomal activity against Trypanosoma cruzi 27R27CL1 after 48 hrs
AID764101Mutagenicity in Salmonella typhimurium TA98 at 0.5 to 30 ug/plate after 1 hr by Ames test in absence of S9 fraction2013European journal of medicinal chemistry, Aug, Volume: 66Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agents.
AID632308Ratio of IC50 for blood-stream Trypanosoma brucei brucei expressing type 1 nitroreductase in the absence of tetracycline to IC50 for tetracycline-induced blood-stream Trypanosoma brucei brucei overexpressing type 1 nitroreductase2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents.
AID611499Antitrypanosomal activity against epimastigote forms of Trypanosoma cruzi CL-B5 transfected with Escherichia coli beta-galactosidase gene LacZ at 10 ug/ml after 72 hrs by chlorophenol red-Beta-D-galactopyranoside-based assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Ligand-based discovery of novel trypanosomicidal drug-like compounds: in silico identification and experimental support.
AID1067240Cytotoxicity against mouse J774 cells at 10 ug/mL after 24 hrs by MTT assay2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Antiprotozoan lead discovery by aligning dry and wet screening: prediction, synthesis, and biological assay of novel quinoxalinones.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID472701Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for Trypanosoma cruzi tulahuen C42010Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8
Trypanoside, anti-tuberculosis, leishmanicidal, and cytotoxic activities of tetrahydrobenzothienopyrimidines.
AID547621Cytotoxicity against BESM cells after 88 hrs by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID611503Cytotoxicity against mouse J774 cells assessed as reduction in cell viability at 100 ug/ml after 24 hrs by resazurin-based colorimetric assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Ligand-based discovery of novel trypanosomicidal drug-like compounds: in silico identification and experimental support.
AID1695290Antileishmanial activity against amastigote form of Leishmania infantum MCAN_UY_2015_bPL7 isolate assessed as decrease in parasite viability measured after 72 hrs by resazurin assay2020RSC medicinal chemistry, Aug-01, Volume: 11, Issue:8
AID1766395Antileishmanial activity against wild type Leishmania donovani promastigotes incubated for 72 hrs by resazurin dye based assay2021ACS medicinal chemistry letters, Sep-09, Volume: 12, Issue:9
Monocyclic Nitro-heteroaryl Nitrones with Dual Mechanism of Activation: Synthesis and Antileishmanial Activity.
AID491694Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13
Synthesis, structural elucidation and in vitro antiparasitic activity against Trypanosoma cruzi and Leishmania chagasi parasites of novel tetrahydro-1-benzazepine derivatives.
AID337144Antitrypanosomal activity against Trypanosoma cruzi M6241CL6 after 48 hrs
AID781028Cytotoxicity against human THP1 cells by AlamarBlue assay2013Bioorganic & medicinal chemistry letters, Dec-01, Volume: 23, Issue:23
Synthesis and anti-parasitic activity of a novel quinolinone-chalcone series.
AID1272502Trypanocidal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes at 25 uM after 5 days2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Synthesis and biological evaluation of quinoxaline di-N-oxide derivatives with in vitro trypanocidal activity.
AID1361365Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi INC-5 infected in NIH mouse blood assessed as parasite lysis after 24 hrs by optical microscopic method2018European journal of medicinal chemistry, Aug-05, Volume: 156Synthesis, molecular docking and biological evaluation of novel phthaloyl derivatives of 3-amino-3-aryl propionic acids as inhibitors of Trypanosoma cruzi trans-sialidase.
AID1766401Antileishmanial activity against Leishmania donovani LdBOB derived from MHOM/SD/62/1 S-CL2D promastigotes overexpressing NTR1 incubated for 72 hrs by resazurin dye based assay2021ACS medicinal chemistry letters, Sep-09, Volume: 12, Issue:9
Monocyclic Nitro-heteroaryl Nitrones with Dual Mechanism of Activation: Synthesis and Antileishmanial Activity.
AID547620Antitrypanosomal activity against Trypanosoma cruzi PSD-I infected in BESM cells measured after 88 hrs postinfection by HTS assay2010Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8
Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.
AID565941Therapeutic index, ratio of IC50 for chinese hamster V79 cells to IC50 for Trypanosoma brucei BSF2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Trypanocidal activity of aziridinyl nitrobenzamide prodrugs.
AID1070002Selectivity index, ratio of LC50 for mouse NCTC-929 cells to IC50 for amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID106021Tested for cytotoxicity towards human MRC-5 cells2002Bioorganic & medicinal chemistry letters, Dec-16, Volume: 12, Issue:24
Antitrypanosomal activities and cytotoxicity of 5-nitro-2-furancarbohydrazides.
AID337147Antitrypanosomal activity against Trypanosoma cruzi Y after 48 hrs
AID1486935Antiprotozoal activity against Leishmania mexicana MHOM/MX/ISETGS incubated for 72 hrs by Neubauer chamber based cell counting method2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis, in vitro and in vivo giardicidal activity of nitrothiazole-NSAID chimeras displaying broad antiprotozoal spectrum.
AID252080Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 10 mg/mL after incubation for 98 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID263381Unspecific cytotoxicity against murine J774 macrophages at 1 ug/ml2006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
New ligand-based approach for the discovery of antitrypanosomal compounds.
AID611501Antitrypanosomal activity against amastigote forms of Trypanosoma cruzi CL-B5 expressing Escherichia coli LacZ gene infected in NCTC929 fibroblasts at 1 ug/ml after 7 days by chlorophenol red-Beta-D-galactopyranoside-based assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Ligand-based discovery of novel trypanosomicidal drug-like compounds: in silico identification and experimental support.
AID1592305Selectivity index, ratio of CC50 for mouse J774.A1 cells to IC50 for antileishmanial activity against Leishmania mexicana MNYC-BZ/62/M379 promastigotes
AID214979In vitro anti-protozoal parasite activity against Trypanosoma cruzi TC-12003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
1,4-Dihydroxy-2,3-dioxatricyclo[8.4.0.0(4,9)]tetradecane and derivatives with in vitro activity against Plasmodium falciparum, Trypanasoma b brucei, Trypanasoma cruzi, and Leishmaniasis infantum.
AID597224Selectivity index, ratio of ID50 for mouse J774 cells to ID50 for Trypanosoma cruzi Tulahuen 2 epimastigotes2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.
AID548300Antimicrobial activity against Trypanosoma brucei gambiense2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID779137Prodrug conversion assessed as Trypanosoma brucei brucei recombinant his-tagged nitroreductase-mediated NADH oxidization by spectrophotometric analysis2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
Novel 3-nitro-1H-1,2,4-triazole-based piperazines and 2-amino-1,3-benzothiazoles as antichagasic agents.
AID565945Cytotoxicity against african green monkey Vero cells after 6 days by Alamar blue assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Trypanocidal activity of aziridinyl nitrobenzamide prodrugs.
AID337151Antitrypanosomal activity against Trypanosoma cruzi 31R16CL1 after 48 hrs
AID1147549Antiprotozoal activity against Trypanosoma cruzi BH infected in CFW mouse assessed as increase in host mean survival time at 200 mg/kg, po administered daily for 5 days starting 4 hrs post-parasite infection (Rvb = 14 +/- 1 days)1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID723217Trypanocidal activity against Trypanosoma brucei rhodesiense Z310 after 72 hrs by Alamar blue assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
A class of 5-nitro-2-furancarboxylamides with potent trypanocidal activity against Trypanosoma brucei in vitro.
AID473011Inhibition of Trypanosoma brucei rhodesiense recombinant rhodesain by standard fluorescence assay2010Journal of medicinal chemistry, Mar-11, Volume: 53, Issue:5
Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids.
AID437110Toxicity in CD1 mouse assessed as survival at 300 mg/kg, ip after 3 days2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID1202550Antimicrobial activity against bloodstream trypomastigote stage of Trypanosoma cruzi INC-5 after 24 hrs by Brener method2015European journal of medicinal chemistry, , Volume: 96Design, synthesis and biological evaluation of quinazoline derivatives as anti-trypanosomatid and anti-plasmodial agents.
AID1132883Antitrypanosomal activity against Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood at 13 mg/kg/day, intramuscular treatment started on day 10 of infection up to day 141977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
AID1147547Antiprotozoal activity against Trypanosoma cruzi BH infected in CFW mouse assessed as increase in host mean survival time at 10 mg/kg, ip administered daily for 5 days starting 4 hrs post-parasite infection (Rvb = 14 +/- 1 days)1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID1187959Trypanocidal activity against trypomastigote form of Trypanosoma cruzi infected in african green monkey Vero cells assessed as cell viability after 5 to 7 days by MTT assay2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
2-Phenylaminonaphthoquinones and related compounds: synthesis, trypanocidal and cytotoxic activities.
AID1321007Selectivity index, ratio of CC50 for human U2OS cells infected with amastigote stage of Trypanosoma cruzi Y to EC50 for amastigote stage of Trypanosoma cruzi Y2016European journal of medicinal chemistry, Oct-04, Volume: 121Design, synthesis and antitrypanosomal activity of some nitrofurazone 1,2,4-triazolic bioisosteric analogues.
AID265555Antitrypanosomatid activity against Trypanosoma cruzi Tulahuen 2 epimastigote form2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
2H-benzimidazole 1,3-dioxide derivatives: a new family of water-soluble anti-trypanosomatid agents.
AID353670Cytotoxicity against human THP1 cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Synthesis and in vitro activity of new tetrahydronaphtho[1,2-b]azepine derivatives against Trypanosoma cruzi and Leishmania chagasi parasites.
AID1422888Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Discovery of a Biologically Active Bromodomain Inhibitor by Target-Directed Dynamic Combinatorial Chemistry.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1706433Antitrypanosomal activity against Trypanosoma cruzi Tulahuen strain C2C4 amastigotes infected in rat 3T3 cells assessed as reduction in parasite growth incubated for 48 hrs by chlorophenol red-fl-D-galactopyranoside based colorimetric analysis2020European journal of medicinal chemistry, Dec-01, Volume: 207Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
AID252083Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 100 mg/mL after incubation for 48 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID1070005Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition at 1 uM after 7 days by beta-galactosidase reporter gene assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID1300858Antitrypanosomal activity against wild type bloodstream form of Trypanosoma brucei brucei assessed as inhibition of parasite growth after 3 days by resazurin assay2016European journal of medicinal chemistry, Jul-19, Volume: 117Antitrypanosomal activity of 5-nitro-2-aminothiazole-based compounds.
AID1754872Trypanocidal activity against Trypanosoma brucei gambiense assessed as reduction in intracellular ATP production incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay2021Bioorganic & medicinal chemistry, 07-15, Volume: 42Synthesis and evaluation of trypanocidal activity of derivatives of naturally occurring 2,5-diphenyloxazoles.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID525498Antiparasitic activity against Trypanosoma brucei BSF after 3 days by Alamar blue assay2010Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3
Exploiting the drug-activating properties of a novel trypanosomal nitroreductase.
AID1147552Antiprotozoal activity against Trypanosoma cruzi BH infected in CFW mouse assessed as increase in host mean survival time at 25 mg/kg, po administered daily for 5 days starting 4 hrs post-parasite infection (Rvb = 14 +/- 1 days)1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID764120Selectivity index, ratio of IC50 for mouse J774 cells to IC50 for epimastigotes of Trypanosoma cruzi Y2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
5-Nitro-2-furfuriliden derivatives as potential anti-Trypanosoma cruzi agents: design, synthesis, bioactivity evaluation, cytotoxicity and exploratory data analysis.
AID1320594Inhibition of human mitochondrial HSP60/HSP10-ATPase activity expressed in Escherichia coli DH5alpha/BL21 (DE3) assessed as inhibition of denatured MDH refolding preincubated for 10 mins followed by ATP addition measured after 40 to 60 mins by malachite g2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.
AID723480Trypanocidal activity against bloodstream form of N-(4-(allyloxy)-3-(trifluoromethyl)phenyl)-5-nitrofuran-2-carboxamide-resistant Trypanosoma brucei after 72 hrs by Alamar blue assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
A class of 5-nitro-2-furancarboxylamides with potent trypanocidal activity against Trypanosoma brucei in vitro.
AID764115Antichagasic activity against epimastigote form of Trypanosoma cruzi Tulahuen 2 assessed as parasite growth inhibition measured on day 52013European journal of medicinal chemistry, Aug, Volume: 66Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agents.
AID647777Antitrypanosomal activity against Trypanosoma cruzi clone CL-Brener epimastigotes after 14 days by alamar blue assay2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Synthesis and antikinetoplastid activity of a series of N,N'-substituted diamines.
AID437121Toxicity in CD1 mouse liver at 300 mg/kg, ip after 3 days by histological study2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID1162122Antiparasitic activity against epimastigote stage of Trypanosoma cruzi infected in Vero cells assessed as parasite growth inhibition after 24 hrs by hemocytometery2014European journal of medicinal chemistry, Oct-30, Volume: 86Synthesis of novel polysubstituted (2SR,4RS)-2-heteroaryltetrahydro-1,4-epoxy-1-benzazepines and cis-2-heteroaryl-4-hydroxytetrahydro-1H-1-benzazepines as antiparasitic agents.
AID337138Antitrypanosomal activity against Trypanosoma cruzi 13379 CL5 after 48 hrs
AID629708Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as inhibition of parasite growth at 25 uM after 5 days by spectrophotometric analysis2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Thiosemicarbazones derived from 1-indanones as new anti-Trypanosoma cruzi agents.
AID287714Antitrypanosomatid activity against Trypanosoma cruzi CL Brener epimastigotes assessed as reduction of growth after 5 days2007Bioorganic & medicinal chemistry, Apr-01, Volume: 15, Issue:7
Second generation of 5-ethenylbenzofuroxan derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and structure-activity relationships.
AID1486938Cytotoxicity against African green monkey Vero cells incubated for 24 to 48 hrs by SRB assay2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Synthesis, in vitro and in vivo giardicidal activity of nitrothiazole-NSAID chimeras displaying broad antiprotozoal spectrum.
AID1067242Trypanocidal activity against epimastigote stage of Trypanosoma cruzi CL Brener at 1 ug/mL after 72 hrs by beta-galactosidase reporter gene assay relative to control2014Bioorganic & medicinal chemistry, Mar-01, Volume: 22, Issue:5
Antiprotozoan lead discovery by aligning dry and wet screening: prediction, synthesis, and biological assay of novel quinoxalinones.
AID677573Activity of Trypanosoma brucei brucei recombinant Type I nitroreductase assessed as oxidised NADH level by spectrophotometric analysis2012Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11
Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.
AID1740561Selectivity index, ratio of CC50 for human HepG2 cells to EC50 for Trypanosoma brucei brucei AnTat 1.92020European journal of medicinal chemistry, Sep-15, Volume: 2028-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T. b. brucei and cruzi.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID597231Inhibition of mitochondrial dehydrogenase activity in Trypanosoma cruzi Y epimastigotes at 20 uM up to 120 mins by MTT assay2011Journal of medicinal chemistry, May-26, Volume: 54, Issue:10
3-Trifluoromethylquinoxaline N,N'-dioxides as anti-trypanosomatid agents. Identification of optimal anti-T. cruzi agents and mechanism of action studies.
AID158190In vitro anti-protozoal activity against Plasmodium falciparum Ghana strain; Not determined2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Biological evaluation of substituted quinolines.
AID1147553Antiprotozoal activity against Trypanosoma cruzi BH infected in CFW mouse assessed as increase in host mean survival time at 10 mg/kg, po administered daily for 5 days starting 4 hrs post-parasite infection (Rvb = 14 +/- 1 days)1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID84652Inhibitory activity against proliferation of HTLV-1 transformed cell lines (HUT-102) at 10 uM; ND = Not determined2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Biological evaluation of substituted quinolines.
AID1319974Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition measured after 5 mins by spectrophotometric analysis2016Bioorganic & medicinal chemistry, 11-01, Volume: 24, Issue:21
Synthesis and biological evaluation of N-cyanoalkyl-, N-aminoalkyl-, and N-guanidinoalkyl-substituted 4-aminoquinoline derivatives as potent, selective, brain permeable antitrypanosomal agents.
AID1202576Selectivity index, ratio of IC50 for human LL24 cells to IC50 for Trypanosoma cruzi Y epimastigote forms2015European journal of medicinal chemistry, , Volume: 96Designing and exploring active N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against three Trypanosoma cruzi strains more prevalent in Chagas disease patients.
AID1147555Antiprotozoal activity against Trypanosoma cruzi Y infected in CFW mouse assessed as increase in host mean survival time at 25 mg/kg, po administered daily for 10 days starting 4 hrs post-parasite infection1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID454549Antitrypanosomal activity against Trypanosoma cruzi CL Brener epimastigotes after 5 days2009Bioorganic & medicinal chemistry, Dec-15, Volume: 17, Issue:24
New potent 5-nitroindazole derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and mechanism of action studies.
AID449389Decrease of glucose uptake in Trypanosoma cruzi Y epimastigotes after 4 hrs relative to control2009European journal of medicinal chemistry, Nov, Volume: 44, Issue:11
Second generation of 2H-benzimidazole 1,3-dioxide derivatives as anti-trypanosomatid agents: synthesis, biological evaluation, and mode of action studies.
AID1351076Antitrypanosomal activity against Trypanosoma cruzi Y Tc2 amastigotes infected in human U2OS cells up to 200 uM after 72 hrs by Draq5 staining based HCS analysis relative to control2018European journal of medicinal chemistry, Jan-20, Volume: 144Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
AID491695Antitrypanosomal activity against Trypanosoma cruzi 320I01 epimastigotes after 72 hrs by haemocytometry2010Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13
Synthesis, structural elucidation and in vitro antiparasitic activity against Trypanosoma cruzi and Leishmania chagasi parasites of novel tetrahydro-1-benzazepine derivatives.
AID723483Cytotoxicity against human HeLa cells after 65 hrs by Alamar blue assay2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
A class of 5-nitro-2-furancarboxylamides with potent trypanocidal activity against Trypanosoma brucei in vitro.
AID437118Toxicity in CD1 mouse assessed as glutamic-pyruvate transaminase level at 450 mg/kg, po after 3 days2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID214322In vitro inhibitory dose against epimastigote form of Trypanosoma cruzi Brener strain2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Quinoxaline N,N'-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi. Structure-activity relationships.
AID1596479Selectivity index, ratio of IC50 for human AB943 cells to IC50 of bloodstream form of Trypanosoma brucei gambiense Feo2019European journal of medicinal chemistry, Jul-15, Volume: 174Thiazolidinone/thiazole based hybrids - New class of antitrypanosomal agents.
AID1140922Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as growth inhibition after 5 days2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activity.
AID353669Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay2009Bioorganic & medicinal chemistry letters, Apr-15, Volume: 19, Issue:8
Synthesis and in vitro activity of new tetrahydronaphtho[1,2-b]azepine derivatives against Trypanosoma cruzi and Leishmania chagasi parasites.
AID214323In vitro inhibitory dose against epimastigote form of Trypanosoma cruzi Tulahuen strain2004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Quinoxaline N,N'-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi. Structure-activity relationships.
AID333391Cytotoxicity against african green monkey Vero cells after 4 hrs by MTT assay2004Journal of natural products, Oct, Volume: 67, Issue:10
Novel cassane and cleistanthane diterpenes from Myrospermum frutescens: absolute stereochemistry of the cassane diterpene series.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1361363Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi NINOA infected in NIH mouse blood assessed as reduction in parasite lysis after 24 hrs by optical microscopic method2018European journal of medicinal chemistry, Aug-05, Volume: 156Synthesis, molecular docking and biological evaluation of novel phthaloyl derivatives of 3-amino-3-aryl propionic acids as inhibitors of Trypanosoma cruzi trans-sialidase.
AID1592302Antileishmanial activity against Leishmania mexicana MNYC-BZ/62/M379 promastigotes assessed as growth inhibition measured after 24 hrs by MTT assay
AID317677Growth inhibition of Trypanosoma cruzi epimastigotes Tulahuen 22008Bioorganic & medicinal chemistry, Mar-01, Volume: 16, Issue:5
Imidazolidines as new anti-Trypanosoma cruzi agents: biological evaluation and structure-activity relationships.
AID723482Selectivity index, ratio of EC50 for human HeLa cells to EC50 for bloodstream form of Trypanosoma brucei brucei 4272013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
A class of 5-nitro-2-furancarboxylamides with potent trypanocidal activity against Trypanosoma brucei in vitro.
AID337134Antitrypanosomal activity against Trypanosoma cruzi Z1 after 48 hrs
AID1277395Antiparasitic activity against Trypanosoma cruzi Y trypomastigotes infected in rhesus monkey LLC-MK2 cells followed by re-infection of amastigotes in human U2OS cells assessed as reduction in parasite infection level after 96 hrs by draq5 staining based a2016European journal of medicinal chemistry, Feb-15, Volume: 109Highly improved antiparasitic activity after introduction of an N-benzylimidazole moiety on protein farnesyltransferase inhibitors.
AID454551Cytotoxicity against human Caco-2 cells at 25 uM by MTT assay2009Bioorganic & medicinal chemistry, Dec-15, Volume: 17, Issue:24
New potent 5-nitroindazole derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and mechanism of action studies.
AID303379Antitrypanosomal activity against Trypanosoma cruzi CL Brener2007Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24
In vivo anti-Chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives.
AID1713358Ratio of IC50 for blood stream form of Trypanosoma brucei brucei assessed as growth inhibition expressing elevated level of type 1 nitroreductase incubated for 72 hrs followed by alamar blue addition further incubated for 16 hrs to IC50 for blood stream f2016European journal of medicinal chemistry, Nov-10, Volume: 123Nitrotriazole-based acetamides and propanamides with broad spectrum antitrypanosomal activity.
AID253513Inhibitory concentration against wild-type (427) with NAC Trypanosoma brucei2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID1147551Antiprotozoal activity against Trypanosoma cruzi BH infected in CFW mouse assessed as increase in host mean survival time at 50 mg/kg, po administered daily for 5 days starting 4 hrs post-parasite infection (Rvb = 14 +/- 1 days)1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID693342Growth inhibition of epimastigote form of Trypanosoma cruzi CL-B5 at 256 uM after 72 hrs by lacZ reporter gene assay2012European journal of medicinal chemistry, Dec, Volume: 58Synthesis, biological evaluation and chemometric analysis of indazole derivatives. 1,2-Disubstituted 5-nitroindazolinones, new prototypes of antichagasic drug.
AID1147550Antiprotozoal activity against Trypanosoma cruzi BH infected in CFW mouse assessed as increase in host mean survival time at 100 mg/kg, po administered daily for 5 days starting 4 hrs post-parasite infection (Rvb = 14 +/- 1 days)1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID214311Growth inhibition of the intracellular Trypanosoma cruzi was measured by counting percentage of myoblasts with Trypanosoma cruzi parasite after 72 hr (absence of compound)1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi.
AID1254924Antimicrobial activity against bloodstream forms of Trypanosoma brucei brucei overexpressing type I nitroreductase assessed as reduction in cell viability after 3 days by alamar blue assay in absence of tetracycline2015European journal of medicinal chemistry, Oct-20, Volume: 1033-Nitrotriazole-based piperazides as potent antitrypanosomal agents.
AID632307Antitrypanosomal activity against tetracycline-induced blood-stream Trypanosoma brucei brucei overexpressing type 1 nitroreductase after 3 days by alamar blue assay2011Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23
Novel 3-nitro-1H-1,2,4-triazole-based aliphatic and aromatic amines as anti-chagasic agents.
AID1596478Cytotoxicity against human AB943 cells assessed as reduction in cell viability after 5 days resazurin dye based fluorescence assay2019European journal of medicinal chemistry, Jul-15, Volume: 174Thiazolidinone/thiazole based hybrids - New class of antitrypanosomal agents.
AID247964Concentration causing cytotoxicity to 50% of L-6 rat skeletal myoblasts2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID454783Increase in squalene biosynthesis in Trypanosoma cruzi tulahuen 2 epimastigotes at ID50 concentration per 8 x 10'6 cells/ml after 120 mins by HPLC analysis (Rvb=0.6 to 2.1 ug/ml)2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene.
AID311102Cytotoxicity against human NCI-H4602007Journal of natural products, Aug, Volume: 70, Issue:8
Hydroxyalkenylresorcinols from Stylogyne turbacensis.
AID337143Antitrypanosomal activity against Trypanosoma cruzi MIL4CL10 after 48 hrs
AID764116Antichagasic activity against epimastigote form of Trypanosoma cruzi Tulahuen 2 assessed as parasite growth inhibition at 25 uM measured on day 5 relative to control2013European journal of medicinal chemistry, Aug, Volume: 66Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agents.
AID1147561Antiprotozoal activity against high myocardial tissue infiltration leishmanial form of Trypanosoma cruzi BHC/10 infected in CFW mouse assessed as increase in host mean survival time at 25 mg/kg, po administered daily for 10 days starting 4 hrs post-parasi1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID337148Antitrypanosomal activity against Trypanosoma cruzi A99CL7 after 48 hrs
AID1507193Cytotoxicity against mouse J774 cells assessed as reduction in cell viability after 48 hrs by MTT assay2017European journal of medicinal chemistry, Aug-18, Volume: 136Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.
AID437128Toxicity in CD1 mouse heart at 450 mg/kg, po after 3 days by histological study2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID565944Antitrypanosomal activity against Trypanosoma brucei BSF overexpressing NTR gene assessed as growth inhibition after 3 days by Alamar blue assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
Trypanocidal activity of aziridinyl nitrobenzamide prodrugs.
AID1742372Selectivity index, ratio of CC50 for human HepG2 cells to EC50 for Trypanosoma brucei brucei trypomastigotes AnTat 1.9
AID548278Antimicrobial activity against wild type Trypanosoma brucei assessed as growth doubling time2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID494146Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes2010Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16
Anti-T. cruzi activities and QSAR studies of 3-arylquinoxaline-2-carbonitrile di-N-oxides.
AID213656Concentration required to inhibit proliferation of the epimastigote form of Trypanosoma cruzi1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi.
AID1422891Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for Trypanosoma cruzi Dm28c amastigotes infected in African green monkey Vero cells2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Discovery of a Biologically Active Bromodomain Inhibitor by Target-Directed Dynamic Combinatorial Chemistry.
AID1254926Ratio of IC50 for bloodstream forms of Trypanosoma brucei brucei overexpressing type I nitroreductase in absence of tetracycline to IC50 for bloodstream forms of Trypanosoma brucei brucei overexpressing type I nitroreductase in presence of tetracycline2015European journal of medicinal chemistry, Oct-20, Volume: 1033-Nitrotriazole-based piperazides as potent antitrypanosomal agents.
AID491698Selectivity index, CC50 for african green monkey Vero cells to IC50 for Trypanosoma cruzi 320I01 amastigotes2010Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13
Synthesis, structural elucidation and in vitro antiparasitic activity against Trypanosoma cruzi and Leishmania chagasi parasites of novel tetrahydro-1-benzazepine derivatives.
AID1507207Genotoxicity in Salmonella typhimurium TA98 at 1 ug/plate in absence of mouse liver S9 fraction by Ames test2017European journal of medicinal chemistry, Aug-18, Volume: 136Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.
AID1165095Trypanocidal activity against bloodstream forms of Trypanosoma brucei brucei Lister 427 clone 221a overexpressing type I nitroreductase assessed as inhibition of proliferation after 3 days by resazurin assay in absence of tetracycline2014European journal of medicinal chemistry, Nov-24, Volume: 87Novel nitro(triazole/imidazole)-based heteroarylamides/sulfonamides as potential antitrypanosomal agents.
AID1706437Selectivity index, ratio of IC50 for cytotoxicity against rat 3T3 cells to IC50 for antitrypanosomal activity against Trypanosoma cruzi Tulahuen strain C2C4 amastigotes infected in rat 3T3 cells2020European journal of medicinal chemistry, Dec-01, Volume: 207Re-evaluating pretomanid analogues for Chagas disease: Hit-to-lead studies reveal both in vitro and in vivo trypanocidal efficacy.
AID1147564Acute toxicity in ip dosed CFW mouse administered daily for 5 days1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID437101Growth inhibition of Trypanosoma cruzi Tulahuen 2 epimastigote at 5 uM after 5 days2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID1070010Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition at 32 uM after 7 days by beta-galactosidase reporter gene assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID333390Antitrypanosomal activity against intracellular Trypanosoma cruzi Tulahuen clone C4 assessed as cleavage of chlorophenol red-beta-D-galactosidase2004Journal of natural products, Oct, Volume: 67, Issue:10
Novel cassane and cleistanthane diterpenes from Myrospermum frutescens: absolute stereochemistry of the cassane diterpene series.
AID263385Antitrypanosomal activity against Trypanosoma cruzi infected NMRI mice at 50 mg/kg/day2006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
New ligand-based approach for the discovery of antitrypanosomal compounds.
AID1632142Antitrypanosomal activity against epimastigote forms of Trypanosoma cruzi INC-5 isolated from chagas disease patient after 24 hrs by resazurin dye based spectrophotometric analysis2016Bioorganic & medicinal chemistry letters, 09-01, Volume: 26, Issue:17
Synthesis and trypanocidal activity of novel benzimidazole derivatives.
AID1254925Antimicrobial activity against bloodstream forms of Trypanosoma brucei brucei overexpressing type I nitroreductase assessed as reduction in cell viability after 3 days by alamar blue assay in presence of tetracycline2015European journal of medicinal chemistry, Oct-20, Volume: 1033-Nitrotriazole-based piperazides as potent antitrypanosomal agents.
AID486232Cytotoxicity against mouse J774 cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Jun, Volume: 45, Issue:6
Naftifine-analogues as anti-Trypanosoma cruzi agents.
AID265557Antitrypanosomatid activity against Trypanosoma cruzi Y epimastigote form2006Journal of medicinal chemistry, Jun-01, Volume: 49, Issue:11
2H-benzimidazole 1,3-dioxide derivatives: a new family of water-soluble anti-trypanosomatid agents.
AID263378Antitrypanosomal activity against Trypanosoma cruzi epimastigotes at 1 ug/ml2006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
New ligand-based approach for the discovery of antitrypanosomal compounds.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1507194Selectivity index, ratio of IC50 for mouse J774 cells to IC50 for Trypanosoma cruzi Tulahuen 2 epimastigotes2017European journal of medicinal chemistry, Aug-18, Volume: 136Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.
AID1507208Genotoxicity in Salmonella typhimurium TA98 up to 0.5 ug/plate in absence of mouse liver S9 fraction by Ames test2017European journal of medicinal chemistry, Aug-18, Volume: 136Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.
AID437102Toxicity in CD1 mouse assessed as decrease in weight respect to day zero at 450 mg/kg, po after 3 days2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID1351074Cytotoxicity against human U2OS cells assessed as reduction in cell viability2018European journal of medicinal chemistry, Jan-20, Volume: 144Investigating the structure-activity relationships of N'-[(5-nitrofuran-2-yl) methylene] substituted hydrazides against Trypanosoma cruzi to design novel active compounds.
AID392036Toxicity against Trypanosoma cruzi infected CD1 mouse assessed as effect on kidney histology at 300 mg/kg, ip2008European journal of medicinal chemistry, Oct, Volume: 43, Issue:10
In vivo studies of 5-arylethenylbenzofuroxans in acute murine models of Chagas' disease.
AID252073Percent of growth inhibition of Trypanosoma cruzi (Y strain) epimastigote forms at compound concentration of 1 mg/mL after incubation for 48 hr2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Synthesis and in vitro antitrypanosomal activity of novel Nifurtimox analogues.
AID454772Selectivity index, ratio of IC50 for mouse J774 cells to ID50 for Trypanosoma cruzi tulahuen 22009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene.
AID494145Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as inhibition of parasite growth at 25 uM relative to control2010Bioorganic & medicinal chemistry letters, Aug-15, Volume: 20, Issue:16
Anti-T. cruzi activities and QSAR studies of 3-arylquinoxaline-2-carbonitrile di-N-oxides.
AID1507195Growth inhibition of Trypanosoma cruzi clone CL B5 epimastigotes at 25 uM after 72 hrs by beta-galactosidase reporter gene assay relative to control2017European journal of medicinal chemistry, Aug-18, Volume: 136Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.
AID723220Selectivity ratio of EC50 for bloodstream form of N-(4-(allyloxy)-3-(trifluoromethyl)phenyl)-5-nitrofuran-2-carboxamide-resistant Trypanosoma brucei to EC50 for bloodstream form of wild type Trypanosoma brucei brucei 4272013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
A class of 5-nitro-2-furancarboxylamides with potent trypanocidal activity against Trypanosoma brucei in vitro.
AID1459828Anti-parasitic activity against Trypanosoma cruzi Dm28c epimastigotes in logarithmic phase measured after 24 to 48 hrs by resazurin assay2017European journal of medicinal chemistry, Jan-05, Volume: 125Rational design of nitrofuran derivatives: Synthesis and valuation as inhibitors of Trypanosoma cruzi trypanothione reductase.
AID437112Toxicity in CD1 mouse assessed as leukocyte level at 450 mg/kg, po after 3 days2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID1428304Antitrypanosomal activity against Trypanosoma brucei brucei 427 bloodstream forms after 24 hrs by propidium iodide dye based flow cytometry2017European journal of medicinal chemistry, Jan-27, Volume: 126In vitro activity and mode of action of distamycin analogues against African trypanosomes.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1742375Antitrypanosomal activity against blood stream form of Trypanosoma brucei brucei S427 trypomastigotes overexpressing NTR1 assessed as inhibition of parasite growth
AID356067Cytotoxicity against HFF after 3 days by MTT assay2003Journal of natural products, Jul, Volume: 66, Issue:7
Five new cassane diterpenes from Myrospermum frutescens with activity against Trypanosoma cruzi.
AID1742374Antitrypanosomal activity against blood stream form of wild type Trypanosoma brucei brucei S427 trypomastigotes assessed as inhibition of parasite growth
AID393024Selectivity index, ratio of IC50 for human HeLa cells to IC50 for Trypanosoma cruzi Tulahuen 2 epimastigotes2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
New potent imidazoisoquinolinone derivatives as anti-Trypanosoma cruzi agents: biological evaluation and structure-activity relationships.
AID629709Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as inhibition of parasite growth after 5 days by spectrophotometric analysis2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Thiosemicarbazones derived from 1-indanones as new anti-Trypanosoma cruzi agents.
AID647776Antitrypanosomal activity against Trypanosoma brucei MITat 427 clone 221a trypomastigotes after 3 days by alamar blue assay2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Synthesis and antikinetoplastid activity of a series of N,N'-substituted diamines.
AID1147559Antiprotozoal activity against Trypanosoma cruzi Peru infected in CFW mouse assessed as increase in host mean survival time at 10 mg/kg, po administered daily for 10 days starting 4 hrs post-parasite infection1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID548284Selectivity ratio of EC50 for Trypanosoma brucei NfxR2 to EC50 for Trypanosoma brucei2010Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7
Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
AID1070009Antimicrobial activity against amastigote stage of Trypanosoma cruzi CL Brener infected in mouse NCTC-929 cells assessed as growth inhibition at 16 uM after 7 days by beta-galactosidase reporter gene assay2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
In vitro phenotypic screening of 7-chloro-4-amino(oxy)quinoline derivatives as putative anti-Trypanosoma cruzi agents.
AID391026Cytotoxicity against african green monkey Vero cells by MTT assay2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Synthesis, cytotoxicity, and anti-Trypanosoma cruzi activity of new chalcones.
AID700326Activity of His-tagged Trypanosoma brucei nitroreductase assessed as oxidation of NADH2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
Design, synthesis, and evaluation of potential prodrugs of DFMO for reductive activation.
AID1320597Inhibition of pig heart native MDH reporter reaction after 20 to 40 mins by fluorescence based assay2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.
AID482888Inhibition of human liver cathepsin B at 100 uM2009Journal of medicinal chemistry, Sep-24, Volume: 52, Issue:18
On-bead screening of a combinatorial fumaric acid derived peptide library yields antiplasmodial cysteine protease inhibitors with unusual peptide sequences.
AID1470754Trypanocidal activity against trypomastigote stage of Trypanosoma cruzi NINOA infected in NIH mouse blood after 24 hrs by optical microscopic method2017European journal of medicinal chemistry, May-26, Volume: 132An in vitro and in vivo evaluation of new potential trans-sialidase inhibitors of Trypanosoma cruzi predicted by a computational drug repositioning method.
AID1596477Antitrypanosomal activity against bloodstream form of Trypanosoma brucei gambiense Feo reduction in parasite growth after 72 hrs by resazurin dye based fluorescence assay2019European journal of medicinal chemistry, Jul-15, Volume: 174Thiazolidinone/thiazole based hybrids - New class of antitrypanosomal agents.
AID1507192Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes after 5 days2017European journal of medicinal chemistry, Aug-18, Volume: 136Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological properties.
AID243452In vitro inhibitory concentration against P2 aminopurine transporter of Trypanosoma brucei brucei 427 adenosine (0.5 uM) uptake in presence of 1 mM inosine; ND=not determined2005Journal of medicinal chemistry, Aug-25, Volume: 48, Issue:17
Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites.
AID263382Antitrypanosomal activity against Trypanosoma cruzi amastigotes at 100 ug/ml2006Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
New ligand-based approach for the discovery of antitrypanosomal compounds.
AID313395Effect on oxygen uptake in Trypanosoma cruzi Y epimastigotes assessed as rate of oxygen consumption at 180 uM relative to control2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Heteroallyl-containing 5-nitrofuranes as new anti-Trypanosoma cruzi agents with a dual mechanism of action.
AID213964Growth inhibition of the intracellular Trypanosoma cruzi was measured by no. of parasites per 100 myoblasts (T. cruzi ) after 72 hr (absence of compound)1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Structure-activity relationship of new growth inhibitors of Trypanosoma cruzi.
AID1162127Cytotoxicity against African green monkey Vero cells2014European journal of medicinal chemistry, Oct-30, Volume: 86Synthesis of novel polysubstituted (2SR,4RS)-2-heteroaryltetrahydro-1,4-epoxy-1-benzazepines and cis-2-heteroaryl-4-hydroxytetrahydro-1H-1-benzazepines as antiparasitic agents.
AID700325Antitrypanosomal activity against wild type Trypanosoma brucei bloodstream form assessed as growth inhibition after 3 days by Alamar blue assay2012Bioorganic & medicinal chemistry letters, Nov-01, Volume: 22, Issue:21
Design, synthesis, and evaluation of potential prodrugs of DFMO for reductive activation.
AID669377Cytotoxicity against CHO cells assessed as cell viability after 48 hrs by MTT colorimetric assay2012Journal of natural products, May-25, Volume: 75, Issue:5
Indole alkaloids from Geissospermum reticulatum.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID454771Cytotoxicity against mouse J774 cells after 48 hrs by MTT assay2009Bioorganic & medicinal chemistry, Nov-01, Volume: 17, Issue:21
5-Nitrofuranes and 5-nitrothiophenes with anti-Trypanosoma cruzi activity and ability to accumulate squalene.
AID437130Toxicity in CD1 mouse lung at 450 mg/kg, po after 3 days by histological study2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
5-Nitro-2-furyl derivative actives against Trypanosoma cruzi: preliminary in vivo studies.
AID393022Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes after 5 days2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
New potent imidazoisoquinolinone derivatives as anti-Trypanosoma cruzi agents: biological evaluation and structure-activity relationships.
AID1575677Antitrypanosomal activity against Trypanosoma brucei brucei 427 assessed as parasite death after 24 hrs by PI-staining based flow cytometry analysis2019MedChemComm, Aug-01, Volume: 10, Issue:8
Synthesis of bicyclic 1,4-thiazepines as novel anti-
AID1147565Acute toxicity in po dosed CFW mouse administered daily for 5 days1977Journal of medicinal chemistry, Jul, Volume: 20, Issue:7
Antiprotozoal thiazoles. 2. 2-(5-Nitro-2-furyl-, thiazolyl-, and 1-methylimidazolyl-)thiazoles.
AID373855Antitrypanosomal activity against Trypanosoma cruzi CL-Brener clone epimastigotes infected in mouse blood measured on day 5 postinfection by Brener method2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Study of 5-nitroindazoles' anti-Trypanosoma cruzi mode of action: electrochemical behaviour and ESR spectroscopic studies.
AID1300861Ratio of IC50 for bloodstream form of Trypanosoma brucei brucei overexpressing type I nitroreductase in absence of tetracycline to IC50 for bloodstream form of Trypanosoma brucei brucei overexpressing type I nitroreductase in presence of tetracycline2016European journal of medicinal chemistry, Jul-19, Volume: 117Antitrypanosomal activity of 5-nitro-2-aminothiazole-based compounds.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (584)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990112 (19.18)18.7374
1990's64 (10.96)18.2507
2000's112 (19.18)29.6817
2010's229 (39.21)24.3611
2020's67 (11.47)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 57.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index57.30 (24.57)
Research Supply Index6.51 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index96.36 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (57.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials28 (4.35%)5.53%
Reviews75 (11.66%)6.00%
Case Studies28 (4.35%)4.05%
Observational4 (0.62%)0.25%
Other508 (79.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (17)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective, Historically Controlled Study to Evaluate the Efficacy and Safety of a New Pediatric Formulation of Nifurtimox in Children Aged 0 to 17 Years With Chagas' Disease [NCT02625974]Phase 3330 participants (Actual)Interventional2016-01-27Completed
Open-label, Randomized, Single-dose, Cross-over Study to Assess Bioequivalence Between a Single 120 mg Nifurtimox Tablet and a Newly Developed 120 mg Nifurtimox Tablet, Administered Orally Under Fed Conditions to Adult Male and Female Patients With Chroni [NCT03708133]Phase 124 participants (Actual)Interventional2018-12-05Completed
Open-label, Randomized, Single-dose, Cross-over Study to Evaluate the Influence of Dietary Habits on the Pharmacokinetics, Safety, and Tolerability of a 120 mg Dose and to Assess the Relative Bioavailability of a 240 mg Dose of Nifurtimox Tablets Administ [NCT03334838]Phase 136 participants (Actual)Interventional2019-06-10Completed
Cardiovascular Health Investigation and Collaboration From Countries of America to Assess the Markers and Outcomes of Chagas Disease (CHICAMOCHA-3) - EQUITY (Equivalence of Usual Interventions for Trypanosomiasis) [NCT02369978]Phase 2/Phase 3500 participants (Anticipated)Interventional2015-08-31Recruiting
A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma. [NCT00601003]Phase 2112 participants (Actual)Interventional2008-01-14Completed
Effectiveness of Nifurtimox in Patients With Chagas' Disease Based on Data From Patient Medical Records in Argentina: a Retrospective Medical Chart Review Study [NCT03784391]3,000 participants (Actual)Observational2018-12-14Completed
Open Label, Randomized, Single-dose, Cross-over Study to Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bi [NCT03350295]Phase 148 participants (Actual)Interventional2018-06-14Completed
Observational Pregnancy Safety Study of Women Exposed to Nifurtimox During Pregnancy to Describe the Risk of Pregnancy and Maternal Complications and Other Events of Interest on the Developing Fetus, Neonate, and Infant [NCT05477953]50 participants (Anticipated)Observational2022-08-17Recruiting
Non-blinded, Randomized, Single Center, Single Dose, Cross-over Study to Assess the Effect of a High Calorie/High Fat Meal on the Pharmacokinetics of Four 30 mg Nifurtimox Tablets Taken Orally by Adult Male and Female Patients Suffering From Chronic Chaga [NCT02606864]Phase 136 participants (Actual)Interventional2015-12-31Completed
Clinical Study to Assess the Clinical Tolerability, Feasibility and Effectiveness Under Field Conditions of the Combination of Nifurtimox and Eflornithine (NECT) for the Treatment of T.b.Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encepha [NCT00906880]Phase 4630 participants (Actual)Interventional2009-04-30Completed
Clinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic Phase [NCT00146627]Phase 3280 participants (Anticipated)InterventionalCompleted
Clinical Trial Comparing the Therapeutic Combinations Melarsoprol-Nifurtimox, Melarsoprol-Eflornithine and Eflornithine-Nifurtimox in the Treatment of Gambiense Human African Trypanosomiasis in the Meningo-Encephalitic Phase [NCT00330148]Phase 3435 participants Interventional2001-03-31Terminated
Efficacy and Safety of an Eflornithine + Nifurtimox Combination for Treatment of Late-Stage Human African Trypanosomiasis (HAT) in West Nile, Uganda [NCT00489658]Phase 2/Phase 331 participants (Actual)Interventional2002-10-31Terminated(stopped due to Because of unexpectedly reduced disease prevalence in the study area, a pragmatic decision was taken to terminate recruitment in March 2003.)
A Phase I Trial of Nifurtimox for Relapsed or Refractory Neuroblastoma [NCT00486564]Phase 120 participants (Anticipated)Interventional2006-11-30Completed
Efficacy and Safety of Fexinidazole Compared to Nifurtimox-Eflornithine Combination Therapy (NECT) in Patients With Late-stage Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: Pivotal, Non-inferiority, Multicentre, Randomised, Open-label Study [NCT01685827]Phase 2/Phase 3394 participants (Actual)Interventional2012-10-31Completed
Open Label, Randomized, Single Dose Cross-over Study to Assess Bioequivalence Between Single 120 mg Nifurtimox Tablet and Four 30 mg Nifurtimox Tablets Administered Orally, Following High Calorie/High Fat Meal to Adult Male and Female Patients Suffering F [NCT01927224]Phase 137 participants (Actual)Interventional2013-11-30Completed
New Chemotherapy Regimens and Biomarkers for Chagas Disease [NCT03981523]Phase 2450 participants (Anticipated)Interventional2019-12-18Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00601003 (1) [back to overview]Number of Participants With Related Adverse Events as a Measure of Safety and Tolerability
NCT02625974 (35) [back to overview]Number of Subjects With Abnormal ECG Findings Considered as Clinically Significant by Investigators (Part 1)
NCT02625974 (35) [back to overview]Number of Subjects With Abnormal Urinalysis Findings Considered as Clinically Significant or Reported as Adverse Events (AEs)
NCT02625974 (35) [back to overview]Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 1
NCT02625974 (35) [back to overview]Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 10
NCT02625974 (35) [back to overview]Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 11
NCT02625974 (35) [back to overview]Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 9
NCT02625974 (35) [back to overview]Percentage of Participants Cured
NCT02625974 (35) [back to overview]Mean Changes in Vital Signs (Diastolic Blood Pressure) Between the Treatment Groups From Baseline (Part 1)
NCT02625974 (35) [back to overview]Mean Changes in Vital Signs (Heart Rate) Between the Treatment Groups From Baseline (Part 1)
NCT02625974 (35) [back to overview]Mean Changes in Vital Signs (Respiratory Rate) Between the Treatment Groups From Baseline (Part 1)
NCT02625974 (35) [back to overview]Mean Changes in Vital Signs (Systolic Blood Pressure) Between the Treatment Groups From Baseline (Part 1)
NCT02625974 (35) [back to overview]Mean Changes in Vital Signs(Temperature) Between the Treatment Groups From Baseline (Part 1)
NCT02625974 (35) [back to overview]Nifurtimox Concentration Over Time in Plasma at Visit 2 (Part 1)
NCT02625974 (35) [back to overview]Nifurtimox Concentration Over Time in Plasma at Visit 3 (Part 1)
NCT02625974 (35) [back to overview]Nifurtimox Concentration Over Time in Plasma at Visit 6 (Part 1)
NCT02625974 (35) [back to overview]Nifurtimox Concentration Over Time in Plasma at Visit 8 (Part 1)
NCT02625974 (35) [back to overview]Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 3
NCT02625974 (35) [back to overview]Number of Subjects Cured With 60-day Regimen Compared With Historical Active Control (Benznidazole)
NCT02625974 (35) [back to overview]Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 8
NCT02625974 (35) [back to overview]Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
NCT02625974 (35) [back to overview]Number of Subjects With Treatment-emergent High Blood Chemistry Abnormalities by Treatment (Part 1)
NCT02625974 (35) [back to overview]Number of Subjects With Treatment-emergent High Coagulation Abnormalities by Treatment (Part 1)
NCT02625974 (35) [back to overview]Number of Subjects With Treatment-emergent High Hematology Abnormalities by Treatment (Part 1)
NCT02625974 (35) [back to overview]Number of Subjects With Treatment-emergent Low Blood Chemistry Abnormalities by Treatment (Part 1)
NCT02625974 (35) [back to overview]Number of Subjects With Treatment-emergent Low Coagulation Abnormalities by Treatment (Part 1)
NCT02625974 (35) [back to overview]Number of Subjects With Treatment-emergent Low Hematology Abnormalities by Treatment (Part 1)
NCT02625974 (35) [back to overview]Relationship Between Conventional ELISA Results in Terms of Cure or No Cure and IHA Results in All Patients
NCT02625974 (35) [back to overview]Relationship of Conventional Serology (ELISA) to Indirect Hemagglutination Assay (IHA) Results
NCT02625974 (35) [back to overview]Relationship of Conventional Serology (Recombinant ELISA) and Non-conventional (ELISA-F29) Serologic Testing by Visit (Part 1)
NCT02625974 (35) [back to overview]Relationship of Conventional Serology (Total Purified Antigen ELISA) and Non-conventional (ELISA-F29) Serologic Testing by Visit (Part 1)
NCT02625974 (35) [back to overview]Relationship of Conventional Serology (Total Purified Antigen ELISA) and qPCR Testing by Visit (Part 1)
NCT02625974 (35) [back to overview]Number of Subjects With a Positive Serological Response Using Non-conventional Enzyme-linked Immunosorbent Assay-F29 (ELISAF29) Test
NCT02625974 (35) [back to overview]Number of Subjects With Positive Quantitative Polymerase Chain Reaction (qPCR) Results
NCT02625974 (35) [back to overview]Number of Subjects With Positive Results in Concentration Test for T. Cruzi (for Subjects <8 Months of Age)
NCT02625974 (35) [back to overview]Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 6
[back to top]

Number of Subjects With Abnormal ECG Findings Considered as Clinically Significant by Investigators (Part 1)

Clinical significance of abnormal ECG was based on the judgement of the investigator (NCT02625974)
Timeframe: Up to 420 days (Visit 11) post-treatment

InterventionParticipants (Count of Participants)
Nifurtimox 60 Days / Arm 10
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 20

[back to top]

Number of Subjects With Abnormal Urinalysis Findings Considered as Clinically Significant or Reported as Adverse Events (AEs)

Urinalysis was performed and the following parameters evaluated: bilirubin, blood (red blood cells, white blood cells), chorionic gonadotropin β, glucose, ketones, leukocytes, nitrite, pH, protein, specific gravity, and urobilinogen. (NCT02625974)
Timeframe: Up to 420 days (Visit 11) post-treatment

InterventionParticipants (Count of Participants)
Nifurtimox 60 Days / Arm 10
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 20

[back to top]

Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 1

The evaluation was based on clinical examinations. (NCT02625974)
Timeframe: At Visit 1 (before treatment started)

InterventionParticipants (Count of Participants)
Nifurtimox 60 Days / Arm 12
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 20

[back to top]

Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 10

The evaluation was based on clinical examinations. (NCT02625974)
Timeframe: Up to 240 days (Visit 10) post treatment

InterventionParticipants (Count of Participants)
Nifurtimox 60 Days / Arm 11
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 20

[back to top]

Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 11

The evaluation was based on clinical examinations. (NCT02625974)
Timeframe: Up to 420 days (Visit 11) post-treatment

InterventionParticipants (Count of Participants)
Nifurtimox 60 Days / Arm 13
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 23

[back to top]

Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 9

The evaluation was based on clinical examinations. (NCT02625974)
Timeframe: Up to 90 days (Visit 9) post treatment

InterventionParticipants (Count of Participants)
Nifurtimox 60 Days / Arm 11
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 20

[back to top]

Percentage of Participants Cured

"Cure is defined as sero-reduction (in subjects ≥8 months to <18 years of age at randomization) or sero-conversion (in all subjects). Sero-reduction is defined as a ≥20% reduction in optical density [OD]) measured by two conventional ELISA serology tests and sero-conversion is defined as negative Immunoglobulin G (IgG) concentration measured by two conventional ELISA serology tests.~Subjects who have missing conventional serology results at the 12 month time point were treated as failures (ie, no cure).~For the primary objective in the study, superiority over placebo was confirmed if the lower limit of the 95% Confidence Interval (CI) for the nifurtimox (60-day regimen) cure rate is greater than 16%, the larger of the upper limits of the 95% CIs from the two publications." (NCT02625974)
Timeframe: At 12 months post-treatment

InterventionPercentage of participants (Number)
Nifurtimox 60 Days / Arm 132.9
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 218.9

[back to top]

Mean Changes in Vital Signs (Diastolic Blood Pressure) Between the Treatment Groups From Baseline (Part 1)

Diastolic Blood Pressure (NCT02625974)
Timeframe: Baseline and up to 420 days (Visit 11) post-treatment

,
InterventionmmHg (Mean)
VISIT 1VISIT 2VISIT 3VISIT 6VISIT 8VISIT 9VISIT 10VISIT 11
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 20.90-1.000.26-0.140.93-0.210.853.25
Nifurtimox 60 Days / Arm 11.00-1.250.760.260.08-0.680.992.30

[back to top]

Mean Changes in Vital Signs (Heart Rate) Between the Treatment Groups From Baseline (Part 1)

Heart Rate (NCT02625974)
Timeframe: Baseline and up to 420 days (Visit 11) post-treatment

,
InterventionBEATS/MIN (Mean)
VISIT 1VISIT 2VISIT 3VISIT 6VISIT 8VISIT 9VISIT 10VISIT 11
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 20.26-0.75-0.51-0.75-1.34-1.63-3.28-4.66
Nifurtimox 60 Days / Arm 1-1.08-6.750.04-0.78-1.27-1.26-3.28-3.57

[back to top]

Mean Changes in Vital Signs (Respiratory Rate) Between the Treatment Groups From Baseline (Part 1)

Respiratory Rate (NCT02625974)
Timeframe: Baseline and up to 420 days (Visit 11) post-treatment

,
InterventionBREATHS/MIN (Mean)
VISIT 1VISIT 2VISIT 3VISIT 6VISIT 8VISIT 9VISIT 10VISIT 11
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 20.47-1.00-0.14-0.060.04-0.50-0.24-0.74
Nifurtimox 60 Days / Arm 10.12-1.50-0.05-0.57-0.77-1.01-1.36-1.93

[back to top]

Mean Changes in Vital Signs (Systolic Blood Pressure) Between the Treatment Groups From Baseline (Part 1)

Systolic Blood Pressure (NCT02625974)
Timeframe: Baseline and up to 420 days (Visit 11) post-treatment

,
InterventionmmHg (Mean)
VISIT 1VISIT 2VISIT 3VISIT 6VISIT 8VISIT 9VISIT 10VISIT 11
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 20.69-5.00-0.50-1.120.48-0.45-1.481.57
Nifurtimox 60 Days / Arm 11.09-3.751.08-0.74-0.41-0.13-0.021.20

[back to top]

Mean Changes in Vital Signs(Temperature) Between the Treatment Groups From Baseline (Part 1)

Temperature (NCT02625974)
Timeframe: Baseline and up to 420 days (Visit 11) post-treatment

,
Intervention°C (Mean)
VISIT 1VISIT 2VISIT 3VISIT 6VISIT 8VISIT 9VISIT 10VISIT 11
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 20.04-0.030.0400.050.02-0.01-0.10
Nifurtimox 60 Days / Arm 10.01-0.35-0.10-0.06-0.06-0.03-0.07-0.14

[back to top]

Nifurtimox Concentration Over Time in Plasma at Visit 2 (Part 1)

Measured in sub-population. (NCT02625974)
Timeframe: At Visit 2 (Day 1): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours

,
Interventionug/L (Median)
Predose5 - 10 MIN POST10 - 120 MIN POST2 - 4 HOURS POST4 - 8 HOURS POST
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2NA21.149.0300.7289.6
Nifurtimox 60 Days / Arm 1NANA78.2215.4267.6

[back to top]

Nifurtimox Concentration Over Time in Plasma at Visit 3 (Part 1)

Measured in sub-population. (NCT02625974)
Timeframe: At Visit 3 (Day 7): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours

,
Interventionug/L (Median)
Predose5 - 10 MIN POST10 - 120 MIN POST2 - 4 HOURS POST4 - 8 HOURS POST
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 238.356.0232.3257.7267.0
Nifurtimox 60 Days / Arm 147.782.6250.6497.2427.5

[back to top]

Nifurtimox Concentration Over Time in Plasma at Visit 6 (Part 1)

Measured in sub-population. (NCT02625974)
Timeframe: At Visit 6 (Day 30): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours

,
Interventionug/L (Median)
Predose5 - 10 MIN POST10 - 120 MIN POST2 - 4 HOURS POST4 - 8 HOURS POST
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 240.873.7172.7103.8165.2
Nifurtimox 60 Days / Arm 123.871.7135.0369.5249.7

[back to top]

Nifurtimox Concentration Over Time in Plasma at Visit 8 (Part 1)

Measured in sub-population. (NCT02625974)
Timeframe: At Visit 8 (Day 60): Pre-dose and Post-dose at 5-10 minutes, 10-120 minutes, 2-4 hours, and 4-8 hours

,
Interventionug/L (Median)
Predose5 - 10 MIN POST10 - 120 MIN POST2 - 4 HOURS POST4 - 8 HOURS POST
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2NANANANANA
Nifurtimox 60 Days / Arm 1NA92.4139.1395.6300.6

[back to top]

Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 3

The evaluation was based on clinical examinations. (NCT02625974)
Timeframe: Up to 7 days (Visit 3)

,
InterventionParticipants (Count of Participants)
AnemiaChagas diseaseHepatomegalyKnown ECG abnormality
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 20000
Nifurtimox 60 Days / Arm 11214

[back to top]

Number of Subjects Cured With 60-day Regimen Compared With Historical Active Control (Benznidazole)

This exploratory efficacy analysis evaluated the cure rate assessed as seroconversion of nifurtimox after 1-year post-treatment follow-up with that of published data for benznidazole (Sosa Estani et al. 1998 and de Andrade et al. 1996) at 4- and 3-year post-treatment follow-up, respectively, used as historical control. (NCT02625974)
Timeframe: Up to 420 days (Visit 11) post-treatment

InterventionParticipants (Count of Participants)
Nifurtimox 60 Days / Arm 110

[back to top]

Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 8

The evaluation was based on clinical examinations. (NCT02625974)
Timeframe: Up to 60 days (Visit 8) end of treatment

,
InterventionParticipants (Count of Participants)
AnemiaChagas diseaseKnown ECG abnormalityLymphadenopathy
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 20000
Nifurtimox 60 Days / Arm 11111

[back to top]

Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

TEAEs comprised events which first occurred or worsened at or after first application of study drug during the course of the study up to and including 7 days after last application of study drug (NCT02625974)
Timeframe: Up to 420 days (Visit 11) post-treatment

,
InterventionParticipants (Count of Participants)
Any treatment-emergent adverse event (TEAE)Any Serious TEAE
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2663
Nifurtimox 60 Days / Arm 11476

[back to top]

Number of Subjects With Treatment-emergent High Blood Chemistry Abnormalities by Treatment (Part 1)

"The Number Analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.~The number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline." (NCT02625974)
Timeframe: Up to 420 days (Visit 11) post-treatment

,
InterventionParticipants (Count of Participants)
Creatinine (mg/dL)Albumin (g/dL)Alkaline Phosphatase (U/L)Alanine Aminotransferase (U/L)Aspartate Aminotransferase (U/L)Bilirubin (mg/dL)Direct Bilirubin (mg/dL)Blood Urea Nitrogen (mg/dL)Urate (mg/dL)Glucose (mg/dL)Protein (g/dL)
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 222137799311314
Nifurtimox 60 Days / Arm 134911192719211171542

[back to top]

Number of Subjects With Treatment-emergent High Coagulation Abnormalities by Treatment (Part 1)

"The Number Analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.~The number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline." (NCT02625974)
Timeframe: Up to 420 days (Visit 11) post-treatment

,
InterventionParticipants (Count of Participants)
Prothrombin Time (sec) in PlasmaActivated Partial ThromboplastinTime in Plasma Prothrombin Intl. Normalized Ratio
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2231013
Nifurtimox 60 Days / Arm 138921

[back to top]

Number of Subjects With Treatment-emergent High Hematology Abnormalities by Treatment (Part 1)

"The number analyzed represents the number of subjects at baseline with a normal or lower than normal laboratory assessment who also had at least one valid laboratory value after start of treatment. Subjects with missing or high abnormal values at baseline are not included in the number analyzed.~The number of subjects represents subjects with at least one high laboratory assessment after start of treatment who had a normal or lower than normal laboratory assessment at baseline." (NCT02625974)
Timeframe: Up to 420 days (Visit 11) post-treatment

,
InterventionParticipants (Count of Participants)
Hematocrit (%)Hemoglobin (g/dL)Erythrocytes (T/L) in BloodEry. Mean Corpuscular Volume (fL) in BloodEry. Mean Corpuscular Hemoglobin (pg) in BloodEry. Mean Corpuscular HGB Conc. (g/dL) in BloodLeukocytes (GIGA/L) in BloodNeutrophils/Leukocytes (%)Neutrophils (GIGA/L)Lymphocytes/Leukocytes (%)Lymphocytes (GIGA/L)Monocytes/Leukocytes (%)Monocytes (GIGA/L)Eosinophils/Leukocytes (%)Eosinophils (GIGA/L)Basophils/Leukocytes (%)Basophils (GIGA/L)Platelets (GIGA/L) in Blood
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 283975616128177171526227213
Nifurtimox 60 Days / Arm 1191521201423413836352133175853201027

[back to top]

Number of Subjects With Treatment-emergent Low Blood Chemistry Abnormalities by Treatment (Part 1)

"The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.~The number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline." (NCT02625974)
Timeframe: Up to 420 days (Visit 11) post-treatment

,
InterventionParticipants (Count of Participants)
Creatinine (mg/dL)Albumin (g/dL)Alkaline Phosphatase (U/L)Alanine Aminotransferase (U/L)Aspartate Aminotransferase (U/L)Bilirubin (mg/dL)Direct Bilirubin (mg/dL)Blood Urea Nitrogen (mg/dL)Urate (mg/dL)Glucose (mg/dL)Protein (g/dL)
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 21044353015181815
Nifurtimox 60 Days / Arm 122144617031322917

[back to top]

Number of Subjects With Treatment-emergent Low Coagulation Abnormalities by Treatment (Part 1)

"The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.~The number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline." (NCT02625974)
Timeframe: Up to 420 days (Visit 11) post-treatment

,
InterventionParticipants (Count of Participants)
Prothrombin Time (sec) in PlasmaActivated Partial ThromboplastinTime in Plasma Prothrombin Intl. Normalized Ratio
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2525
Nifurtimox 60 Days / Arm 1101514

[back to top]

Number of Subjects With Treatment-emergent Low Hematology Abnormalities by Treatment (Part 1)

"The number analyzed represents the number of subjects at baseline with a normal or higher than normal laboratory assessment who also had at least one valid laboratory value after start of treatment.~The number of subjects represents subjects with at least one low laboratory assessment after start of treatment who had a normal or higher than normal laboratory assessment at baseline." (NCT02625974)
Timeframe: Up to 420 days (Visit 11) post-treatment

,
InterventionParticipants (Count of Participants)
Hematocrit (%)Hemoglobin (g/dL)Erythrocytes (T/L) in BloodEry. Mean Corpuscular Volume (fL) in BloodEry. Mean Corpuscular Hemoglobin (pg) in BloodEry. Mean Corpuscular HGB Conc. (g/dL) in Blood *Leukocytes (GIGA/L) in BloodNeutrophils/Leukocytes (%)Neutrophils (GIGA/L)Lymphocytes/Leukocytes (%)Lymphocytes (GIGA/L)Monocytes/Leukocytes (%)Monocytes (GIGA/L)Eosinophils/Leukocytes (%)Eosinophils (GIGA/L)Basophils/Leukocytes (%)Basophils (GIGA/L)Platelets (GIGA/L) in Blood
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2171796102118272590282255223
Nifurtimox 60 Days / Arm 130231516192939534640554331314116

[back to top]

Relationship Between Conventional ELISA Results in Terms of Cure or No Cure and IHA Results in All Patients

"Cure is defined as sero-reduction (in subjects => 8 months to < 18 years of age at randomization) or sero-conversion (in all subjects).~Sero-reduction is defined as a => 20% reduction in optical density [OD]) measured by two conventional ELISA serology tests and sero-conversion is defined as negative Immunoglobulin G [IgG] concentration measured by two conventional ELISA serology tests." (NCT02625974)
Timeframe: Up to 420 days (Visit 11) post-treatment

,,,,
InterventionParticipants (Count of Participants)
Nifurtimox 60 daysNifurtimox 30 days
Cure and Non Reactive/Reactive Decreasing5417
Cure and Reactive Non-decreasing184
No Cure and Missing IHA Testing10
No Cure and Non Reactive/Reactive Decreasing6138
No Cure and Reactive Non-decreasing7649

[back to top]

Relationship of Conventional Serology (ELISA) to Indirect Hemagglutination Assay (IHA) Results

Sero-reduction is defined as a => 20% reduction in optical density [OD]) using two conventional ELISA serology tests in subjects => 8 months to < 18 years of age at randomization; Others: reactive results that are not sero-reduction in subjects => 8 months to < 18 years of age at randomization; or reactive results in subjects < 8 months of age at randomization. (NCT02625974)
Timeframe: Up to 420 days (Visit 11) post-treatment

,,,,,,,,,
InterventionParticipants (Count of Participants)
Nifurtimox 60 daysNifurtimox 30 days
Non-react ELISA and React IHA Nochange00
Non-reactive ELISA and Non-reactive IHA84
Non-reactive ELISA and Reactive IHA Decrease21
Reactive ELISA: Others and Missing IHA10
Reactive ELISA: Others and Non-reactive IHA11
Reactive ELISA: Others and React IHA Decrease6037
Reactive ELISA: Others and React IHA Nochange7649
Reactive ELISA: Sero Reduction and Reactive IHA Decrease4212
Reactive ELISA: Sero-reduction and Non-react IHA20
Reactive ELISA: Sero-reduction and Reactive IHA Nochange184

[back to top]

Relationship of Conventional Serology (Recombinant ELISA) and Non-conventional (ELISA-F29) Serologic Testing by Visit (Part 1)

Using frequencies of matches and mismatches to assess agreement (NCT02625974)
Timeframe: Up to 420 days (Visit 11) post-treatment

,,,,,,,
InterventionParticipants (Count of Participants)
Visit 1Visit 3Visit 6Visit 8Visit 10Visit 11
Nifurtimox 30 Days Non-reactive and Non-reactive111156
Nifurtimox 30 Days Non-reactive and Reactive000021
Nifurtimox 30 Days Reactive and Non-reactive384342434348
Nifurtimox 30 Days Reactive and Reactive726467635953
Nifurtimox 60 Days Non-reactive and Non-reactive0021108
Nifurtimox 60 Days Non-reactive and Reactive000023
Nifurtimox 60 Days Reactive and Non-reactive7785819091106
Nifurtimox 60 Days Reactive and Reactive14213313112410893

[back to top]

Relationship of Conventional Serology (Total Purified Antigen ELISA) and Non-conventional (ELISA-F29) Serologic Testing by Visit (Part 1)

Using frequencies of matches and mismatches to assess agreement (NCT02625974)
Timeframe: Up to 420 days (Visit 11) post-treatment

,,,,,,,
InterventionParticipants (Count of Participants)
Visit 1Visit 3Visit 6Visit 8Visit 10Visit 11
Nifurtimox 30 Days Non-reactive and Non-reactive111166
Nifurtimox 30 Days Non-reactive and Reactive000000
Nifurtimox 30 Days Reactive and Non-reactive384342434248
Nifurtimox 30 Days Reactive and Reactive726467636154
Nifurtimox 60 Days Non-reactive and Non-reactive000098
Nifurtimox 60 Days Non-reactive and Reactive000023
Nifurtimox 60 Days Reactive and Non-reactive7785839192106
Nifurtimox 60 Days Reactive and Reactive14213313112410893

[back to top]

Relationship of Conventional Serology (Total Purified Antigen ELISA) and qPCR Testing by Visit (Part 1)

Using frequencies of matches and mismatches to assess agreement (NCT02625974)
Timeframe: Up to 420 days (Visit 11) post-treatment

,,,,,,,,,,,
InterventionParticipants (Count of Participants)
Visit 1Visit 8Visit 10Visit 11
Nifurtimox 30 Days Missing Conventional Testing Non-detectable0100
Nifurtimox 30 Days Non-reactive Detectable0000
Nifurtimox 30 Days Non-reactive Non-detectable1166
Nifurtimox 30 Days Reactive Detectable57125
Nifurtimox 30 Days Reactive Non Evaluable1221
Nifurtimox 30 Days Reactive Non-detectable521039996
Nifurtimox 60 Days Non-reactive Detectable0000
Nifurtimox 60 Days Non-reactive Non-detectable001111
Nifurtimox 60 Days Reactive Detectable117333
Nifurtimox 60 Days Reactive Non Evaluable1221
Nifurtimox 60 Days Reactive Non-detectable99210195194
Nifurtimox 60 Days Reactive qPCR Missing2001

[back to top]

Number of Subjects With a Positive Serological Response Using Non-conventional Enzyme-linked Immunosorbent Assay-F29 (ELISAF29) Test

The non-conventional ELISA-F29 test is considered an early marker of treatment efficacy in chronic Chagas disease. (NCT02625974)
Timeframe: Up to 420 days (Visit 11) post-treatment

InterventionParticipants (Count of Participants)
Visit 172591461Visit 172591462Visit 372591461Visit 372591462Visit 672591461Visit 672591462Visit 872591461Visit 872591462Visit 1072591461Visit 1072591462Visit 1172591462Visit 1172591461
Non-reactiveMissingReactive
Nifurtimox 60 Days / Arm 1142
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 272
Nifurtimox 60 Days / Arm 177
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 239
Nifurtimox 60 Days / Arm 10
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 20
Nifurtimox 60 Days / Arm 1133
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 264
Nifurtimox 60 Days / Arm 185
Nifurtimox 60 Days / Arm 11
Nifurtimox 60 Days / Arm 1131
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 267
Nifurtimox 60 Days / Arm 183
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 243
Nifurtimox 60 Days / Arm 15
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 21
Nifurtimox 60 Days / Arm 1124
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 263
Nifurtimox 60 Days / Arm 191
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 244
Nifurtimox 60 Days / Arm 14
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 24
Nifurtimox 60 Days / Arm 1110
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 261
Nifurtimox 60 Days / Arm 1101
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 248
Nifurtimox 60 Days / Arm 18
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 22
Nifurtimox 60 Days / Arm 196
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 254
Nifurtimox 60 Days / Arm 1114
Nifurtimox 60 Days / Arm 19
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 23

[back to top]

Number of Subjects With Positive Quantitative Polymerase Chain Reaction (qPCR) Results

The qPCR is molecular technique, considered a tool to diagnose acute and congenital Chagas disease, as well as a marker to measure treatment failure when demonstrating positive (detectable) results (NCT02625974)
Timeframe: Up to 420 days (Visit 11) post-treatment

InterventionParticipants (Count of Participants)
Visit 172591461Visit 172591462Visit 372591461Visit 372591462Visit 672591461Visit 672591462Visit 872591461Visit 872591462Visit 1072591461Visit 1072591462Visit 1172591462Visit 1172591461
Non-detectableNon-evaluableMissingDetectable
Nifurtimox 60 Days / Arm 199
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 253
Nifurtimox 60 Days / Arm 1117
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 257
Nifurtimox 60 Days / Arm 11
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 20
Nifurtimox 60 Days / Arm 1171
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 286
Nifurtimox 60 Days / Arm 146
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 221
Nifurtimox 60 Days / Arm 10
Nifurtimox 60 Days / Arm 12
Nifurtimox 60 Days / Arm 1207
Nifurtimox 60 Days / Arm 14
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 22
Nifurtimox 60 Days / Arm 15
Nifurtimox 60 Days / Arm 1210
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2105
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 21
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 23
Nifurtimox 60 Days / Arm 1206
Nifurtimox 60 Days / Arm 18
Nifurtimox 60 Days / Arm 1205
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2102
Nifurtimox 60 Days / Arm 13
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 25
Nifurtimox 60 Days / Arm 110

[back to top]

Number of Subjects With Positive Results in Concentration Test for T. Cruzi (for Subjects <8 Months of Age)

(NCT02625974)
Timeframe: Up to 90 days (Visit 9) post-treatment

InterventionParticipants (Count of Participants)
Visit 172591461Visit 172591462Visit 372591461Visit 372591462Visit 672591461Visit 672591462Visit 872591461Visit 872591462Visit 972591461Visit 972591462
PositiveNegativeMissing
Nifurtimox 60 Days / Arm 112
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 27
Nifurtimox 60 Days / Arm 10
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 20
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 21
Nifurtimox 60 Days / Arm 111
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 25
Nifurtimox 60 Days / Arm 11

[back to top]

Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 6

The evaluation was based on clinical examinations. (NCT02625974)
Timeframe: Up to 30 days (Visit 6)

,
InterventionParticipants (Count of Participants)
Known ECG abnormalityRomana sign
Nifurtimox 30 Days, Then Placebo 30 Days / Arm 201
Nifurtimox 60 Days / Arm 110

[back to top]